The species specific effects of Mesenchymal stem cell conditioned medium on proliferating mouse and rat adult neural stem, progenitor cells by Dechant, Franz - Xaver
AUS DEM LEHRSTUHL 
FÜR NEUROLGIE 
PROF. DR. MED. ULRICH BOGDAHN 
DER FAKULTÄT FÜR MEDIZIN 
DER UNIVERSITÄT REGENSBURG 
 
 
The species specific effects of Mesenchymal stem cell 
conditioned medium on proliferating mouse and rat adult 
neural stem/ progenitor cells 
 
 
 
 
 
 
 
 
 
 
Inaugural - Dissertation 
zur Erlangung eines Doktorgrades 
der Medizin 
 
 
der 
Fakultät für Medizin 
der Universität Regensburg 
 
 
vorgelegt von 
Franz – Xaver Dechant 
Regensburg, 2011 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AUS DEM LEHRSTUHL 
FÜR NEUROLGIE 
PROF. DR. MED. ULRICH BOGDAHN 
DER FAKULTÄT FÜR MEDIZIN 
DER UNIVERSITÄT REGENSBURG 
 
 
 
The species specific effects of Mesenchymal stem cell 
conditioned medium on proliferating mouse and rat adult 
neural stem/ progenitor cells 
 
 
 
 
 
Inaugural - Dissertation 
zur Erlangung eines Doktorgrades 
der Medizin 
 
 
der 
Fakultät für Medizin 
der Universität Regensburg 
 
 
 
 
 
 
vorgelegt von 
Franz – Xaver Dechant 
Regensburg, Anno Domini 2011 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dekan: Prof. Dr. Dr. Torsten Reichert 
1. Berichterstatter Prof. Dr. rer. nat. Ludwig Aigner 
2. Berichterstatter PD Dr. med. Martin Proeschodt 
Tag der Mündlichen Prüfung: 29. März 2012 
IN ACKNOLEDGEMENT OF MY GREAT 
GRATITUDE DEDICATED TO REBECCA 
MAYR.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
οὐ γάρ ἐστιν κρυπτὸν ὃ οὐ φανερὸν 
γενήσεται οὐδὲ ἀπόκρυφον ὃ οὐ µὴ 
γνωσθῇ καὶ εἰς φανερὸν ἔλθῃ. 
 
Lk 8, 17  
 
 
FOR THERE IS NOTHING HIDDEN THAT WILL NOT BE 
DISCLOSED, AND NOTHING CONCEALED THAT WILL 
NOT BE KNOWN OR BROUGHT OUT INTO THE OPEN. 
LUKE 8, 17 
  
 
CONTENT - VI -
 
Content  
 
Content ..................................................................................................................... VI 
Figure legend........................................................................................................... IX 
Table legend.............................................................................................................. X 
List of abbreviations ............................................................................................... XI 
Zusammenfassung................................................................................................XIV 
Abstract ...................................................................................................................XV 
I. Introduction............................................................................................................ 1 
I.1 Nervous system: Functions and main cell types ................................................ 1 
I.2 Stem cells and progenitor cells .......................................................................... 2 
I.3. Adult stem cells................................................................................................. 4 
I.3.1 Concept and biology.................................................................................... 4 
I.3.2 Bone marrow derived mesenchymal stem cells (MSCs) ............................. 5 
I.3.3 Adult neurogenesis and gliogenesis............................................................ 6 
I.4. NSCs in vitro: Neurospheres biology and the Oligodendrogenic program (OPr)
.............................................................................................................................. 10 
I.5 Reciprocal influence of neural and mesenchymal stem cells ........................... 13 
II. Aim of the thesis................................................................................................. 16 
III. Materials and methods...................................................................................... 17 
III.1 Materials ........................................................................................................ 17 
III.1.1. Expendable materials ............................................................................. 17 
III.1.2. Reagents and media for cell culture ....................................................... 18 
III.1.3. Other reagents for cell culture ................................................................ 19 
III.1.4. Kits & master mix.................................................................................... 19 
III.1.5. Other chemicals and reagents................................................................ 19 
III.1.6. Buffer, solutions and stock solutions ...................................................... 20 
III.1.7. Devices................................................................................................... 21 
III.1.8. Software ................................................................................................. 21 
III.2. Cell culture methods ..................................................................................... 22 
  
 
CONTENT - VII - 
 
III.2.1. MSC cultures.......................................................................................... 22 
III.2.2. Preparation of NSCs primary cultures .................................................... 22 
III.2.3. Cultivation and passaging of adult NSCs ............................................... 23 
III.2.4. Cell counting........................................................................................... 23 
III.2.5. Preparation of MSC-conditioned media.................................................. 24 
III.2.6. Coating of coverslips with poly-L-ornithin and laminin............................ 24 
III.2.7. Phenotype and fate analysis of NSph..................................................... 24 
III.2.8. Immunofluorescence analysis and quantification ................................... 25 
III.2.9 FACS analysis (Ki67) .............................................................................. 27 
III.2.10 CytoTox96®Non-Radioactive Cytotoxicity Assay .................................. 27 
III.3 Molecular Methods......................................................................................... 28 
III.3.1. RNA – Extraction from Neurospheres .................................................... 28 
III.3.2 cDNA synthesis ....................................................................................... 29 
III.3.2 Quantitative PCR..................................................................................... 30 
III.3.3 Gel electrophoresis of DNA ..................................................................... 30 
III.4. Statistics........................................................................................................ 30 
IV. Results ............................................................................................................... 31 
IV.1. Effects of MSC-CM on proliferating rNSphs ................................................. 31 
IV.1.1. MSC-CM promotes adhesion of proliferating rNSphs and affects cell 
morphology........................................................................................................ 31 
IV.1.2. MSC-CM has no effect on the absolute number of rNSphs in vitro ........ 32 
IV.1.3. MSC-CM does not affect the highly expression pattern of glial and 
oligodendroglial progenitor markers on proliferating rNSphs............................. 33 
IV.1.4. MSC-CM enhances rNSphs oligodendrogenic response after growth 
factor withdrawal ............................................................................................... 36 
IV.1.5. MSC-CM primed the oligodendrogenic program on proliferating rNSphs
.......................................................................................................................... 38 
IV. 2. Effects of MSC-CM on proliferating mNSphs............................................... 41 
  
 
 - VIII - 
 
IV.2.1. MSC-CM promotes proliferating mNSphs adhesion affecting cell 
morphology........................................................................................................ 41 
IV.2.2 MSC-CM treatment decreases the absolute number of mNSphs in vitro 42 
IV.2.3 MSC-CM enhances the expression pattern of glial and progenitor markers 
of proliferating mNSphs..................................................................................... 43 
IV.2.4. MSC-CM enhances the expression of neural stem cell markers in 
proliferating mNSphs......................................................................................... 46 
IV.2.5 MSC-CM increases the rate of apoptosis of mNSphs and led the mNSphs 
to stem cells ...................................................................................................... 48 
IV.2.6 MSC-CM enhances the expression of the markers of self renewal......... 50 
V. Discussion.......................................................................................................... 51 
V.1 MSC-CM primes the oligodendrogenic program in proliferating adult rNSCs. 51 
V.2 MSC-CM enhances the expression of astrocyte / stem cells markers on 
proliferating adult mNSCs ..................................................................................... 54 
V.3 In vivo clinical relevance of MSCs and NPCs interaction................................ 58 
VI. References......................................................................................................... 60 
Curriculum vitae ..................................................................................................... 74 
Acknowledgements.............................................................................................. 110 
Declaration / Erklärung ........................................................................................ 111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
FIGURE LEGEND - IX -
 
Figure legend 
 
Figure 1. Different characters of stem cells and progenitor/precursor cells. .............. 3 
Figure 2. Regulation of neurogenesis. ..................................................................... 10 
Figure 3. Oligodendrogenesis and the oligodendrogenic program. ......................... 12 
Figure 4. Morphology of proliferating rNSphs. ......................................................... 32 
Figure 5. MSC-CM has not any significant influence on the growth-bearing of 
proliferating rNSphs.................................................................................. 33 
Figure 6. Marker expression profile of proliferating rNSphs pre-incubated 21 days 
under control condition, 50% MSC-CM and 100% MSC-CM.................... 35 
Figure 7. Growth factor withdrawal response of rNSphs pre-incubated 21 days under 
control condition, 50% MSC-CM and 100% MSC-CM.............................. 38 
Figure 8. Effects of MSC-CM on the oligodendrogenic capacity of proliferating 
rNSphs. .................................................................................................... 40 
Figure 9. Morphology of proliferating mNSphs......................................................... 42 
Figure 10. MSC-CM treatment decreases the absolute cell-number of mNSphs in 
vitro........................................................................................................... 43 
Figure 11. Marker expression profile of proliferating mNSphs pre-incubated 21 days 
under control conditions, 50% MSC-CM and 100% MSC-CM.................. 45 
Figure 12. Growth factor withdrawal response of mNSphs pre-incubated 21 days 
under control condition, 50% MSC-CM and 100% MSC-CM.................... 48 
Figure 13. Treatment with MSC-CM induces apoptosis/ necrosis in proliferating 
mNSphs and led the cells to the G0- state of the cell- cycle..................... 49 
Figure 14.Treatment with MSC-CM enhances the expression of markers of cell self 
renewal. .................................................................................................... 50 
 
 
 
  
 
TABLE LEGEND - X -
 
Table legend 
 
Table 1 Primary antibodies used......................................................................................... 26 
Table 2 Secondary antibodies used ................................................................................... 26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
LIST OF ABBREVIATIONS - XI -
 
List of abbreviations  
 
α-MEM  Alpha Modified Eagles Medium 
A2B5 Progenitor marker 
B-27 supplement serum substitute to support the cultures of neurons at 
low or high cell densities in both short and long term 
cultures 
BMP bone morphogenetic protein 
BrdU  Bromo-deoxyuridine 
cDNA  Complementary DNA 
CNPase Oligodendrocytes Marker 
CNS  Central nervous system 
CNTF Ciliary neurothropic factor 
CO2 Carbon dioxide  
DAPI 4’, 6’-diamidino-2-phenylindole dihydrochloride hydrate 
DCs Dendritic cells  
DCX  Doublecortin 
DG Dentate gyrus  
DMEM  Dulbecco’s Modified Eagle’s Medium 
DNA  Desoxyribonucleotide acid 
EGF  Epidermal growth factor 
FACS Fluorescence-Activated Cell Sorter 
FGF Basic fibroblast growth factor 
FSGB Fish Skin Gelatin Buffer 
FOX-O Forkhead box, class O) 
GAPDH  Glycerinaldehyde-3-Phosphate-Dehydrogenase 
GFAP  Glial Acidic Fibrilary Protein 
GFW growth factor withdrawal 
h hour 
HC  Hippocampus 
HSC  Haematopoietic stem cell  
Id Inhibitor of differentiation 
i.e. id est  
IGF-1 Insulin-like growth factor 
  
 
LIST OF ABBREVIATIONS - XII - 
 
IL-6  Interleukin 6 
LDH Lactate dehydrogenase 
LV Lateral ventricle 
M mol 
MAP2ab  Microtubule-associated Protein 2a + 2b 
MBP  Myelin Basic Protein 
MEM  Modified Eagles Medium 
MgSO4 Magnesium sulphate 
mNSph Mouse Neurospheres 
mRNA  messenger RNA 
MSC Mesenchymal stem cell 
MSC-CM Mesenchymal stem cell conditioned medium 
MS Multiple sclerosis 
NPC Neural progenitor cell 
NSC Neural stem cell 
NSPCs Adult derived neural stem/progenitor cells 
NSph Neurospheres 
O4  Oligodendrocytes Marker 
Olig-1/-2  Oligodendrocytes transcription factor 1/2 
OPC  Oligodendrocytes Progenitor Cell 
OPr Oligodendrogenic program 
PBS  Phosphate buffered NaCl-solution 
PCR  Polymerase chain reaction 
PDGF-A Platelet-Derived Growth Factor A  
PFA  Paraform aldehyde 
PI  Propidium Iodide 
PI3K-Akt Phosphatidylinositol 3-kinase-Akt 
PNS peripheral nervous system 
PSA NCAM Poly-Sialated Neural Cell Adhesion Molecule 
rNSph  Rat Neurospheres 
RT  Reverse transcriptase 
RT-PCR  Reverse transcriptase polymerase chain reaction 
SD  Standard deviation 
SMI94  Antibody against Myelin Basic Protein 
  
 
LIST OF ABBREVIATIONS - XIII - 
 
Sox2  SRY (sex determining region Y)-box 2 
TGF-beta1 transforming growth factor type-beta-1 
SVZ Subventricular zone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 - XIV - 
 
 
Zusammenfassung 
 
In den verschiedenen Geweben des erwachsenen Organismus kommen un-
terschiedliche Arten von Stammzellen vor. Dazu gehören neben Mesenchymalen 
Stammzellen aus dem Knochenmark (MSCs), Neuronale Stamm und Progenitor Zel-
len (NSPCs) aus verschiedenen Regionen des Zentralen Nervensystems (CNS). 
Diese NSPCs können in der Form von Neurospheres (NSph) als in vitro Modell für 
die adulte Neuro- und Gliogenese kultiviert werden.  
Auch wenn die zu Grunde liegenden Mechanismen ungeklärt sind, zeigten in vitro 
Experimente, dass von MSCs produzierte lösliche Faktoren in speziesspezifischer 
Weise neuroprotektiv und neuroregenerativ wirken. So lassen diese löslichen Fakto-
ren differenzierende NSphs der Ratte zu Oligodendrozyten ausreifen (Rivera et al., 
2006). Im Gegensatz dazu führen diese Mediatoren zur Astro- und Neurogenese dif-
ferenzierender NSphs bei der Maus (Bai et al., 2007). Diese Linienspezifizierung der 
Zellidentität von Stammzellen tritt allerdings nicht nur während der Differenzierungs-
phase, sondern bereits im Proliferationsstadium auf. Vor diesem Hintergrund unter-
sucht die vorliegende Doktorarbeit ob lösliche Mediatoren von MSCs fähig sind die 
Zellidentität proliferierender NSphs zu primen oder sie zu verändern. Im Weiteren 
geht diese Arbeit der Frage nach, ob diese Effekte in speziesspezifischer Weise auf-
treten. 
Um diese Fragenstellungen zu klären, wurden proliferierende NSphs von Maus und 
Ratte mit Nährmedium inkubiert, womit vorher MSCs inkubiert worden waren (MSC-
CM). Im Folgenden wurden die Auswirkungen von MSC-CM, welches die lösliche 
Faktoren der MSCs enthält, auf die Zellmorphologie, die Proliferationsrate, die zell-
spezifische Markerexpression, die Reaktion auf Wachstumsfaktorentzug (GFW) und 
die Expression von neuronalen, astroglialen und oligodendroglialen Markern unter-
sucht. 
Während MSC-CM die Proliferationsrate von rNSphs unbeeinflusst ließ, führte es zur 
Adhäsion der rNSphs und zur Bildung von zellulären Fortsätzen. Das Progenitormar-
kerprofil der rNSphs war dabei nicht verändert, wohingegen die Ausreifung zu MBP-
positiven Oligodendrozyten durch MSC-CM gesteigert wurde. In diesem Zusammen-
hang zeigte sich außerdem, dass der anti-oligodendrogene Transkriptionsfaktor inhi-
  
 
ZUSAMMENFASSUNG - XIV - 
 
bitor of differentiation 2 (Id2) reduziert war, während der pro-oligodendrogene 
Transkriptionsfaktor Olig2 erhöht war. 
 
Im Gegensatz zu diesen Ergebnissen zeigte die Behandlung von mNSphs mit MSC-
CM eine Reduktion der Proliferationsrate und eine Abnahme der absoluten Zellzahl. 
Gleichzeitig führte die Behandlung mit MSC-CM zu einer Erhöhung der Laktatde-
hydrogenasespiegel, verbunden mit der Annahme, dass die im MSC-CM gelösten 
Faktoren zum Zelltod der mNSphs durch Apoptose oder Nekrose führen. Im Gegen-
satz zu rNSphs reiften proliferierende mNSphs nicht zu Oligodendrozyten aus. Aller-
dings fand sich eine Erhöhung von astroglialen Markern ebenso wie eine Erhöhung 
von Stammzellmarkern. Gleichzeitig zeigte sich eine Erhöhung der Selbsterneue-
rungsmarker Bmi-1 und Sox-2, was auf potentielle Stammzellen Rückschlüsse zie-
hen lässt. Auch wenn diese Daten vermuten lassen, dass es sich hierbei um Stamm-
zellen handeln könnte, reichen diese Ergebnisse für einen endgültigen Beweis des 
Stammzellcharakters nicht aus. 
Die in dieser Doktorarbeit beschriebene Möglichkeit in die Biologie proliferierender 
NSPCs einzugreifen, spielt für die Entwicklung neuer medizinischer Therapien eine 
große Rolle. Insbesondere die Bedeutung für die Bereiche der Remyelinisation und 
der autologen Zelltherapie werden durch diese Experimente unterstrichen. 
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Abstract  
 
Adult stem cells reside in different tissues and organs of the adult organism. 
Among these cells are Mesenchymal stem cells (MSCs) and neural stem and pro-
genitor cells (NSPCs). 
NSPCs can be obtained from different regions of the central nervous system (CNS) 
and can be expanded for several passages as neurospheres (NSph) in vitro. These 
NSph cultures are considered as in vitro model for NSPCs neurogenesis and glio-
genesis.  
MSCs, which are located in the bone marrow display neuroprotective, as well as neu-
roregenerative effects on the adult CNS. Although the underlying mechanisms are 
largely unidentified, in vitro experiments revealed that soluble factors derived from 
MSCs affect the adult NSPCs biology in a species-dependent manner. Thus, in a 
previous study Rivera et al. demonstrated that soluble factors derived from MSCs 
induce oligodendrogenesis in differentiating adult rNSPCs (Rivera et al., 2006), 
whereas MSCs induce astro-/ neurogenesis in differentiating adult mNSPCs (Bai et 
al., 2007). However, since lineage specification also occurs in proliferating progeni-
tors and not only during differentiation, this thesis aims to investigate if soluble fac-
tors derived from MSCs are able to prime and / or change the fate of proliferating 
NSphs. Furthermore this dissertation proposes to confirm whether these effects of 
MSC-CM occur in a species dependent manner. Therefore, the effects of conditioned 
medium derived from MSCs (MSC-CM) on adult rat and mouse derived NSph cell 
morphology, proliferation, cell-specific marker expression profile, response to growth 
factor withdrawal (GFW), and the expression of neural, astroglial and oligodendroglial 
fate determinants were analyzed. While MSC-CM did not affect the proliferation rate, 
it induced the formation of cellular processes and the adherence of proliferating 
rNSphs. Even the expression profile of progenitor and precursor markers was not 
affected by MSC-CM in rNSPCs, the formation of MBP positive oligodendrocytes af-
ter GFW was boosted by MSC-CM pre-treatment. Moreover, in proliferating rNSphs, 
MSC-CM reduced the anti-oligodendrogenic determinant inhibitor of differentiation-2 
(Id2), thus increasing the relative proportion of the pro-oligodendrogenic factor Olig2 
expression.  
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However, mNSphs displayed a reduction in the proliferating rate and a reduction of 
the absolute cell number. The increased levels of lactate dehydrogenase (LDH) after 
treatment with MSC-CM indicate that MSCs induced cell death through apoptosis or 
necrosis in proliferating mNSphs.  
Interestingly MSC-CM did not prime mNSPCs towards an oligodendrogenic fate de-
cision, but it let increase the astroglial / and stem cell marker levels. In the same 
manner MSC-CM the self-renewal determinants Bmi1 and Sox-2 were increased af-
ter MSC-CM treatment. Although these data suggest a stem-cell character of these 
remaining mNSphs it is not possible to conclude that they display a full-fully stem cell 
phenotype.  
In summary, soluble factors derived from MSCs prime proliferating rNSPCs towards 
oligodendrogenic fate, whereas it looks like that MSC-CM could shift mNSPCs back 
to a stem cell phenotype. The present findings underscore the potential use of MSCs 
in cell therapies like for example for remyelination or autologous cell therapy. 
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I. Introduction 
 
I.1 Nervous system: Functions and main cell types  
 
By definition the nervous system is the sum of all neural tissues of the body and it 
has three main functions: receiving information from the sensory and the intrinsic 
system, integrating this information and responding with behavioural, cognitive and 
motoric output.  
For the practical use the nervous system is divided in two main parts: the central 
nervous system (CNS), which comprises brain and spinal cord, and the peripheral 
nervous system (PNS), which is composed of the somatic and the visceral nerve sys-
tem. While the PNS is characterized by receiving input and mediating output, the 
CNS is responsible for processing the information in contrast. 
The nervous system mainly consists of two specialized cell types, namely neurons 
and glia cells. Neurons control and integrate all functions of the body. This means 
that neurons receive, integrate and send a signal to a target cell electrochemically.  
The second part of the nervous system is the glia. The term glia or “nerve glue” was 
coined in 1859 by Rudolph Virchow, who interpreted neuroglia as an inactive “con-
nective tissue” holding the neurons together. Today it is well accepted that glia cells 
full-fill multiple functions and are no inactive connective tissue. In general glia cells 
support the physiology and the function of neurons by surrounding them, isolating 
them from each other, supplying them with oxygen and nutrients and the detoxifica-
tion of the environment (Eroglu et Barres, 2010).  
These versatile duties allow to assume that the glia consist of several cell types. The 
glia can be divided into two main categories: macro- and microglia.  
Astrocytes, oligodendrocytes, Schwann-cells and the cells of the ependyme compose 
the macroglia, which is derived from the embryonic ectoderm.  
As their name suggests, astrocytes are star-shaped, process-bearing cells dis-
tributing throughout the CNS. Astrocytes represent the most abundant type of the 
glial cells and full-fill various functions. They form the glia limitans (Squire., 2008), 
assure the K+ and H+ homeostasis, store glycogen and yield glucose to the neurons 
(Jayakumar et Norenberg, 2010; Schousboe et al., 2010). Astrocytes have common 
unique cytological and immunological properties that make them easy to identify, in-
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cluding their star shape, their feeds on capillaries to build the blood brain barrier (glia 
limitans), and a unique population of large bundles of intermediate filaments (Kandel, 
2000). These filaments are composed of an astroglial-specific protein commonly re-
ferred to as glial fibrillary acid protein (GFAP) (Welsch 2005).  
Further tasks of the macroglia are achieved by a second kind of glial cells, 
named oligodendrocytes. These cells are smaller then astrocytes and don’t exhibit 
GFAP-filaments. The main abandonment of oligodendrocytes is the fabrication of 
myelin for the CNS. Myelin itself consists of a single sheet of oligodendroglial plasma 
membrane and builds the myelin sheath. In contrast to the CNS the myelin sheaths 
of the PNS are built by the Schwann- cells. The myelin sheaths have a high electrical 
resistance and insolate the axons.  
An additional type of macroglial cells are the cells of the ependyme. These 
cells are facing the walls of the ventricle system and the central canal of the spinal 
cord. They develop from the embryonic neural epithelium and produce the liquor.  
The second part of the neural glia is the microglia. Microglia is most likely derived 
from bone marrow monocytes that enter the brain during development (Kaur et al., 
2001). In addition to these bone-marrow derived monocytes, mesodermal pial ele-
ments, neural epidermal cells and capillary associated pericytes are told to be the 
source of microglia (Napoli et Neumann, 2009). Microglia cells have been termed 
“the CNS macrophages” and they function as the resident representatives of the im-
mune system in the brain (Navascués et al., 2000).  
 
I.2 Stem cells and progenitor cells 
 
A general definition of the term “stem cell” is the following: Stem cells are undifferen-
tiated, primitive and clonogenic cells which are capable of both self-renewal and mul-
tipotency (Temple, 2006). Self-renewal means the almost unlimited capacity to prolif-
erate and thereby the production of identical cells, while multipotency describes the 
ability to differentiate into a variety of specialized mature cell types (Morrison et al., 
1997; Weissman, 2000). Stem cells are found in almost all multicellular organisms 
and due to their special capacities they are responsible for the development and re-
generation of tissue and organ systems. 
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The differentiation of a stem cell to a mature cell takes place along several stages. 
Thus, the stem cell gives rise to various types of progenitor and precursor cells. 
Among experts the terms progenitor and precursor cell are not used consistent. For 
this reason the following definition of progenitor and precursor cells is used in this 
thesis: progenitor is used to describe any dividing cell that can generate differentiated 
progeny, whether or not it can self-renew. In contrast the term precursor is used to 
describe a cell that is committed to a specific fate. These progenitors and precursors 
finally differentiate into specific mature cells. 
During the lifetime of an organism, tissues must be renewed several thousand times. 
Consequently, stem cells in the basal layer of the accordant tissue must divide for 
several times to produce new full differentiated mature cells for the accordant tissue. 
This process can be maintained only if the stem cell population is self-renewing. 
There are two ways of proliferation to ensure the capacity of self-renewal: symmetric 
and asymmetric division. Symmetric cell division means the genesis of two identic 
daughter cells, with the same fate and the same characteristics, whereas asymmetric 
cell division stands for the generation of one daughter cell that is a new stem cell, like 
the original cell and a second, different cell type with limited self-renewing potential 
and increasing commitment for a particular lineage (fate commitment) (figure 1). 
 
Figure 1. Different characters of stem cells and progenitor/precursor cells. 
A stem cell is an immature cell that has the potential to self-renew and to develop into specialized cell 
types. A stem cell can both produce an additional stem cell with the same characteristics (self-
renewal) or the stem cell is able to develop into a mature, fully-differentiated cell, e.g. a neuron. A 
precursor cell is still capable to proliferate, however with limited self-renewal potential. Here a myeloid 
progenitor cell is shown, producing to specialized cell types (a neutrophil and a red blood cell) (Figure 
extracted from NIH Resources. www.ncbi.nih.gov). 
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I.3. Adult stem cells 
I.3.1 Concept and biology 
 
An adult stem cell is an undifferentiated cell, found among an adult tissue or organ 
that can renew itself and can differentiate to yield some or all of the major specialized 
cell types of the tissue or organ. The primary roles of adult stem cells in a living or-
ganism are to maintain and repair the tissue in which they are found (Basak and Tay-
lor, 2009). Until now several types of stem cells have been described, like haemato-
poietic stem cells (HSC), neural stem cells (NSC), mesenchymal stem cells (MSC) 
and endothelial progenitor cells (Pontikoglou et al., 2008).  
For many years, the general belief was that tissue-residing, multipotent adult stem 
cells were developmentally restricted only to differentiate into cell lineages of the 
specified tissue where they reside, because in contrast to embryonic stem cells, adult 
stem cells are multipotent but not totipotent. 
This traditional view of adult stem cells being restricted in their fate to a specific or-
gan or tissue has challenged in the past few years. In different experimental setups, it 
has been demonstrated that under certain experimental conditions adult stem cell 
may loose their tissue or germ layer-specific phenotypes and become reprogrammed 
to transdifferentiate into cells of other germ layers and tissues (Krause et al., 2001; 
Woodbury et al., 2002). This term transdifferentiation is commonly used to describe 
the plastic ability of adult stem cells to differentiate into cell lineages of tissues differ-
ent from the one in which the somatic stem cell resides and into cells originating from 
other germ layers.  
Although isolated instances of transdifferentiation have been observed in some ver-
tebrate species, whether this phenomenon actually occurs in humans is under de-
bate by the scientific community. Instead of transdifferentiation, the observed in-
stances may involve fusion of a donor cell with a recipient cell equal in vivo (Vassil-
poulos et al., 2003; Weimann et al., 2003; Weinmann et al., 2003; Alvarez-Dolado et 
al., 2003) and in vitro (Terada et al., 2002; Ying et al., 2002). Another possibility is 
that transplanted stem cells are secreting factors that encourage the recipient's own 
stem cells to begin the repair process. Even when transdifferentiation has been de-
tected, only a very small percentage of cells undergo the process (Krabbe et al., 
2005). 
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I.3.2 Bone marrow derived mesenchymal stem cells (MSCs)  
 
The adult bone marrow is a potential rich source of stem cells and it contains two 
types of prototypical multipotent stem cell populations: haematopoietic stem cells 
(HSCs) and mesenchymal stem cells (MSC). Both HSCs and MSCs are of meso-
derm origin and can be distinguished through several adhesion molecules, extracel-
lular matrix proteins, cytokines and growth factor receptors (Bobis et al., 2001).  
MSCs act presumably through paracrine mechanisms as stromal cells to regulate the 
activity and fate of the HSCs in the bone marrow (Mingell et al., 2001). These 
paracrine effects of MSCs are not restricted to the bone marrow niche, as, for exam-
ple MSCs transplantation promoted adult NSPCs proliferation and differentiation in 
an animal model of stroke (Zhang et al., 2004). The effects of these paracrine, solu-
ble factors of MSCs on NSPCs in in vitro models will be discussed in later chapters 
(f.e. I.5). 
Interestingly an increasing amount of researches showed that MSCs are mul-
tipotent adult progenitor cells, which have the capacity to trans-differentiate into cells 
with mesodermal, neuroectodermal and endodermal characteristics in vivo and in 
vitro. Although an increasing amount of studies has reported that transdifferentiation 
of MSCs into neurons and glia cells in vivo and in vitro could supply the repair of 
damaged brain areas (f.e. Dharmasoroja et al. 2009) the results are controversially 
discussed. For in vivo experiments, Azizi et al. transplanted MSCs directly in the 
striatum. Interestingly after three months cells had migrated to the cortex (Azizi et al., 
1998). In another study, MSCs, placed into the mouse lateral ventricle (LV) were later 
detected in cerebellum, HC molecular layer and olfactory bulb. Surprisingly, trans-
planted MSCs expressed markers specific for astrocytes and neuronal lineage. After 
MSCs were placed into a CNS trauma, stroke or Parkinson mouse model, trans-
planted cells were found to express mature astrocyte- or neuronal-specific markers 
(Kopen et al., 1999; Mahmood et al., 2001; Li et al., 2001; Li et al., 2000). However, 
follow-up studies revealed the possibility of fusion events between transplanted 
stem/progenitors cells with endogenous differentiated cells (Kemp et al., 2010; Alva-
rez-Dolado et al., 2003; Terada et al., 2002). 
In vitro studies, which indicate the transdifferentiation of MSCs must be interpreted 
carefully, too. A huge number of studies showed that the induction of neural genes in 
MSCs could be achieved through stimulation with non-physiological substances such 
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as beta mercaptoethanol, dimethylsulfoxide, hydroxyanisole and butylated hydroxy-
toluene, etc. (Deng et al., 2001; Munoz-Elias et al., 2003; Padovan et al., 2003; Ris-
manchi et al., 2003; Sanchez-Ramos et al., 2000; Woodbury et al., 2002; Woodbury 
et al., 2000; Krabbe et al., 2005; Parr et al., 2008). The criteria to assess the neural 
differentiation properties of these compounds were based on the appearance of cells 
exhibiting a typical neural-like morphology and/or the expression of distinctive neural-
specific genes.  
However, further studies have recommended caution in the interpretation of 
results assessing the neural differentiation properties induced by non-physiological 
compounds, since a disruption of the actin cytoskeleton may facilitate the outcome of 
neurite-resembling processes (Neuhuber et al, 2004). When cells were treated with 
cytocalasin-D or latrunculin-A (to disrupt the F-actin network), a neuronal-like mor-
phology was acquired, similar to that obtained with neuronal induction media. More-
over, in a study by Lu and co workers, it was demonstrated that morphological 
changes and increases in immunolabeling for certain neural markers upon “neural 
chemical induction” of MSCs are likely the result of cellular toxicity, cell shrinkage, 
and changes in the cytoskeleton and do not represent a true neuronal differentiation 
(Lu et al., 2004). 
 
I.3.3 Adult neurogenesis and gliogenesis 
 
How the diverse types of neurons and glia are generated by stem and progenitor 
cells during CNS development and in the adulthood is one of the most enthralling 
biological questions. For many years it was believed that the adult CNS is incapable 
of regeneration and that neurogenesis takes place only during embryonic develop-
ment. Now it is commonly accepted that the adult mammalian brain is not simply a 
static postmitotic organ (Seaberg et al., 2003; Taupin et al., 2002; Momma et al., 
2000). The process of the generation of new neurons from stem cells and progenitors 
(neurogenesis), which includes proliferation and fate determination as well as differ-
entiation, maturation and final integration into neural circuits (Ming and Song, 2005) 
is still detectable during adulthood. Since neural stem cells, the source of new neu-
rons were first isolated by Reynold and Weiss from the SVZ of rodents in 1992 and 
by Kukekov 1999 from humans, the cells attract more and more attention of the re-
searchers.  
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Interestingly multipotent cells can be isolated from different regions of the mammal-
ian CNS such as the spinal cord and parenchyma of the adult brain throughout the 
rostrocaudal axis (Johansson et al., 1999, Tend et al., 2002). These data indicate 
that neurogenesis takes place in several areas of the brain, but not everywhere. To 
understand the possibilities and the processes of adult neurogenesis, it is necessary 
to take a look on the areas where adult CNS neurogenesis occurs, named neural 
stem cell niches. A stem cell niche is a constellation of intrinsic and extrinsic cellular 
mechanisms, i.e. signalling molecules like growth factors, cytokines or neurotransmit-
ters and ion concentrations, structure of the extracellular matrix and many others, 
regulating the balance of self renewal and differentiation in stem cells (Moore & 
Lemischka, 2006). The most interesting neural stem cell niches for research are the 
SVZ around the LV and the DG of the HC. The hippocampal stem cell niche is lo-
cated along a thin strip of cells between the hilar region and the granule layer, re-
ferred to as the SGZ (Kempermann et al., 2008). It looks like that the adult neural 
stem cells of the SVZ and the SGZ have a temporal restriction in potency. These 
cells can generate neurons, astrocytes and oligodendrocytes, but the types of neu-
rons and glia generated may be limited. It has been demonstrated that the adult 
NSCs of the SVZ divide and differentiate into neural precursors, which migrate via 
the rostral migratory stream into the olfactory bulb, where they functionally integrate 
and differentiate into granule- and periglomerular neurons (Doetsch & Scharff, 2001; 
Carleton et al., 2003). On the contrary the hippocampal stem cells of the SGZ of the 
DG divide along the border of the hilus locally and give rise to neural precursors, 
which migrate and integrate into the granule layer of the HC (Cameron et al., 1998). 
Furthermore it seems that neural stems of the SVZ and the SGZ cells may be capa-
ble of producing cells for other tissues via transdifferentiation. In 1999, Bjornson et al. 
demonstrated that clonally-derived adult neural stem cells can give rise to haemato-
poietic cells, when they were injected into sublethally irradiated adult mice. Thereaf-
ter it was shown that adult neural stem cells possess the ability to differentiate into 
skeletal-muscle, both in vivo and in vitro (Galli et al. 2000a). 
Although it has been well established that neurogenesis continues in the adult CNS 
the fate and the role of these stem cell populations placed in the different stem cell 
niches remains unclear. Retrograde tracing studies have shown that the newly gen-
erated neuronal cells extend axons (Standfield et al., 1988; Palmer et al, 1999), re-
ceive synaptic input (Markakis et al., 2004) and participate in functional synaptic cir-
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cuitry (Carlen et al., 2002). In addition, it has been hypothesized that these cells have 
diverse functions such as memory (Feng et al., 2001), learning (Kempermann et al., 
2002), and cell replacement (Kokaia et al., 2003). For example there is now growing 
evidence that injury or disease lead to elevated levels of neurogenesis and cell sur-
vival. Ischemic insults have been shown to trigger neurogenesis from neural stem or 
progenitor cells in the SVZ of the LV, the DG of the HC, and even in the spinal cord 
(Kokaia et al., 2003). 
It goes without saying that neurogenesis is a well orchestrated program and must be 
regulated precise. Bmi-1, Sox2 and FoxO3a are characterized more in detail in the 
following, as they are the most important cue transcription factors for this thesis, to 
regulate the activity of NSC (figure 2). Bmi-1 is necessary for NSC self-renewal and 
that it represses the cell cycle inhibitors p16, p19 and p21 (Fasano et al., 2008, 
Molofsky et al., 2003; Molofsky et al., 2005). Foxg1 is a forkhead transcription factor 
that is essential for forebrain development. Loss of Foxg1 in developing cortical cells 
inhibits cell proliferation (Shen et al., 2006). Moreover it is known that Foxg1 inhibits 
p21 levels to stimulate progenitor cell division and acts in part via suppression of p21 
(Fasano et al., 2007). Fasano et al., showed moreover that forced expression of Bmi-
1 increases the Foxg1 levels specifically in proliferating cells and maintains the NSC 
population. Thus, self-renewal is reduced in Bmi-1-deficient NSCs derived from Bmi-
1 knock out mice, which leads postnatal to depletion of these cells. Furthermore, in 
the absence of Bmi-1, the cyclin-dependend kinase inhibitor p16Ink4a is unregulated in 
NSCs leading to a reduced rate of proliferation. Interestingly, restricted neural pro-
genitors from the forebrain proliferate normally in the absence of Bmi-1. That means, 
while self-renewal of NSCs depends on Bmi-1, proliferation of restricted progenitors 
is independent of Bmi-1 (Molowsky et al., 2003). In a lot of other studies the crucial 
role of Sox-2 for the stem cell maintenance in developing and adult brains is demon-
strated (Qu and Shi, 2009). Inhibition of Sox-2 expression results in premature neu-
ronal differentiation, whereas consecutive expression of Sox-2 maintains neural pro-
genitor characteristics and inhibits differentiation (Bylund et al., 2003; Graham et al., 
2003). In addition, over expression of Sox-2 leads to up regulation of Notch and fol-
lowing Hes5 in neural progenitors (Bani-Yaghoub et al., 2006). With a comparable 
importance like Bmi-1 and Sox2, pax6 directly regulates genes, controlling the bal-
ance between neocortical stem cell maintenance, neurogenesis and the production 
of basal progenitors in a dose-dependent manner. Increasing pax6-leves drives basal 
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progenitor cells genesis from cortical stem cells. These basal progenitor cells un-
dergo a limited number of mitotic divisions to generate neurons (Sansom et al., 
2009). Pax6 further interacts with three other regulators of the neurogenesis: Neu-
rog2, Ascl1 and Hes1. 
A further important role in neurogenesis play the FOX-O proteins (Forkhead box, 
class O), a subfamily of Forkhead transcription factors. FOX-O is found in the whole 
body, playing an important role in the energy metabolism, the proliferation, differen-
tiation and survival of stem cells, as well as in many other cellular processes, includ-
ing the apoptosis and DNA repair. These effects are achieved by the induction or 
suppression of target genes. Initially, FOX-O1, FOX-O3a and FOX-O4 were identified 
in fusion genes from chromosomal translocations in human soft-tissue tumours and 
leukemia. In the neural tissues, such as HC, cortex and cerebellum mostly FOX-O3a 
is expressed (Maiese et al. 2008). FOX-O proteins are negatively regulated by the 
phosphatidylinositol 3-kinase-Akt (PI3K-Akt) signalling pathway, which is activated by 
growth factors and cytokines, like Insulin and IGF-1 (Birkenkamp and Coffer, 2003; 
Furukawa-Hibi et al. 2005). The constitutive activation of this signalling pathway 
leads to the development of tumours both through deregulation of cell-cycle progres-
sion and through an increase in cellular resistance to proapoptotic signals. The acti-
vation of the PI3K-Akt signalling pathway appears to be required for the entry of qui-
escent cells into the cell cycle through the suppression of the FOX-O proteins. The 
sustained activity of FOX-O results in up regulation of the expression of p27Kip1, p130 
and cyclin G2, as well as inhibition of the expression of cyclins D and D2, thereby 
ensuring maintenance of the quiescent state. (Furukawa-Hibi et al., 2005). Confluent 
to these conclusions the elimination of FOX-O3a promotes long-term survival of 
neuroblasts and sustains neurogenesis (Siegrist et al., 2011; Chiacchiera and 
Simone, 2010) (figure 2). 
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Figure 2. Regulation of neurogenesis.  
Neurogenesis is a well orchestrated program and must be regulated precise. The most interesting 
transcription factors for this thesis are Bmi-1, Sox-2 and Fox-O3a (red). Bmi-1 is necessary for NSC 
self-renewal and that it represses the cell cycle inhibitors p16, p19 and p21. Bmi-1 further increases 
the Foxg1 levels specifically in proliferating cells and maintains therefore through the inhibition espe-
cially of p21 the NSCs population.  
Consecutive expression of Sox-2 maintains neural progenitor characteristics and inhibits differentia-
tion. Through the inhibition of Cyclin D and D2, Fox-O3a reduces proliferation in NSCs. FOX-O3a itself 
is negatively regulated by the phosphatidylinositol 3-kinase-Akt (PI3K-Akt) signalling pathway, which is 
activated by growth factors and cytokines, like Insulin and IGF-1. 
 
I.4. NSCs in vitro: Neurospheres biology and the Oligodendrogenic 
program (OPr) 
 
As it is not possible to study all aspects of the adult neurogenesis in vivo isolation of 
adult NSCs and their following investigation in culture is necessary. Adult neural stem 
cells can be isolated from several neurogenic and non-neurogenic regions of the 
adult brain, e.g. SVZ, HC, spinal cord, striatum and neocortex (Reynolds and Weiss, 
1992a; Gage et al., 1995; Palmer et al., 1995; Palmer et al., 1999). Usually, the tis-
sue is dissected and dissociated into single cells, which are finally cultured in a de-
fined media supplemented with mitogens, stimulating proliferation like epidermal 
growth factor (EGF) (Reynolds and Weiss, 1992a) and fibroblast growth factor-2 
(FGF-2) (Gritti et al., 1996). Under these proliferation conditions the adult neural stem 
  
 
I. INTRODUCTION - 11 -
 
cells can be cultured as adherent monolayer cultures or as free floating aggregates, 
so called neurospheres (NSph) (Reynolds and Weiss, 1992b; Seaberg and van der 
Kooy, 2002; Wachs et al., 2003b). Through the withdrawal of mitogenic growth fac-
tors and / or adding specific factors NSCs can be encouraged to differentiate into ma-
ture neural cell types. The resulting differentiation fate can be analyzed by standard 
immunocytochemical stainings with antibodies directed against antigens specific for 
one of the three major cell types of the CNS. For the detection of immature neurons 
the polysialylated- neural-cell-adhesions-molecule (PSA-NCAM) is used, whereas 
the microtubule associated protein doublecortin (DCX) and microtubule-associated 
protein 2 isoform a and b (Map2ab) for the location of mature neurons is used (Bern-
hardt and Matus, 1984; Caccamo et al., 1989; Brown et al., 2003). Astrocytes are 
detected through the intermediate filament protein GFAP (Delpech et al., 1978; 
Ghandour et al., 1981) whereas oligodendroglial progenitors can be detected through 
antibodies against A2B5, platelet-derived growth factor receptorα (PDGFR-α) and 
NG2 proteoglycan. In addition immature oligodendrocytes can be detected by the 
expression of galactocerebroside C (GalC) and 2',3'-cyclic nucleotide-3'-
phosphohydrolase (CNPase), while mature oligodendrocytes are detected by the ex-
pression of the myelin basic protein (MBP). Both, mature and immature oligodendro-
cytes are immunopositive against the antibody O4 (Knapp et al., 1988; Watanabe et 
al., 2006). Thus, NSph cultures are useful in vitro models to analyze adult neural 
stem cells properties as well as to explore the properties of NSPCs after the impact 
of MSC-CM. 
As discussed before NSPCs can differentiate in all types of neural cells 
through the addition of different specific mediators after GFW. Rivera et al. showed 
that MSC produce soluble factors, which interact with oligodendrogenesis and in-
struct an oligodendrogenic fate decision on differentiating adult neural stem cells 
(Rivera et al., 2006). 
The production of these oligodendrocytes from NSCs is not a “one step mechanism” 
but a rather process composed of distinct and hierarchically structured event (Liu et 
Rao, 2004; Miller, 2002; de Castro et Bribian., 2005). A lot of extracellular matrix 
components and cell cycle molecules were shown to influence this process. This sig-
nals are orchestrated in a program, here termed oligodendrogenic program (OPr). 
The paracrine mechanisms of MSCs, which are not restricted to the bone marrow 
niche also influence the neural stem cell niche. These soluble factors of MSC, pre-
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sent in MSC-CM strongly activate and promote the OPr in differentiating rNSCs. Ad-
ditionally MSC-CM promotes differentiation and maturation of these cells. This was 
apparently at the expense of astrogenesis, since the number of GFAP-expressing 
cells was dramatically reduced (Rivera et al., 2010; Rivera et al., 2008; Rivera et al., 
2004). To answer the question which factor promotes the effects of MSC-CM on dif-
ferentiating rNSC several factors have been excluded, like insulin-like growth factor-1 
(IGF-1), thyroid hormone (TH), fibroblast growth factor-2 (FGF-2), vascular endothe-
lial growth factor (VEGF), interleukin-6 (IL-6), brain-derived neurotrophic factor 
(BDNF), nerve growth factor (NGF), transforming growth factor beta-1 (TGF-beta1), 
neurotrophin-3 (NT-3), sonic-hedgehog (Shh), PDGF-AA, UDP-glucose and Noggin 
(Rivera et al., 2010; Rivera et al., 2006, Rivera et al., 2008). Importantly, MSCs might 
act via yet unidentified mechanisms through dictating the intracellular modulators of 
the OPr (figure 3). In contrast to the observations of Rivera, Bai et al. showed in 2007 
that MSCs provide humoral signals that selectively promote the genesis of neurons 
and oligodendrocytes from mouse derived mouse NSC. 
 
Figure 3. Oligodendrogenesis and the oligodendrogenic program.  
Myelinating oligodendrocytes are generated from NSPCs that undergo sequential steps of determina-
tion, specification, differentiation, and maturation toward myelinating cells. Proliferating (circular small 
arrow) NSPCs follow a specification step at the “glial branch point” (denoted in the violet square) and 
arise as oligodendroglial progenitors (OPCs). This event might occur directly or by an intermediate 
step in which NSPCs first give rise to proliferating glial progenitors (GPs) that in turn migrate and un-
dergo cell fate decision. Proliferating OPCs migrate and follow a differentiation process toward imma-
ture oligodendrocytes. A maturation process, which involves the activation of myelin gene expression, 
will give rise to myelinating oligodendrocytes. This complete process is highly controlled and regulated 
by an oligodendrogenic program composed by several factors. These factors function either as oli-
godendrogenic inhibitors (in red), activators (in green), or both (bifunctional regulators, in black). Ex-
trinsic components (in boxes) stimulate (arrows) or inhibit (T form) intrinsic components (box-free) via 
signalling pathways. Abbreviations are indicated in the text. (figure extracted from Rivera et al., 2010). 
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It is one aim of this thesis to characterize the effects of MSC-CM on proliferating NSC 
and the interaction with the fate decision of this proliferating NSC, in contrast to the 
existing data, which used differentiating cells for their experiments. Therefore it’s 
known that cells respond different to the same differentiation stimuli, responding on 
the identity and the intrinsic fate, we investigated if MSC-CM can change this intrinsic 
fate of NSCs or can prime this cells. 
 
I.5 Reciprocal influence of neural and mesenchymal stem cells 
 
An increasing amount of studies has demonstrated that intravenously infused MSCs 
are answerable for neuroprotection and regeneration in the lesioned CNS (Dezawa 
et al., 2001; Hofstetter et al., 2002; Lu et al., 2005; Neuhuber et al., 2005; Zhang et 
al., 2005; Zhang et al., 2004; Zhang et al., 2004).  
For example in the case of MS, several studies have demonstrated that intravenously 
infused MSCs reduce demyelisation, increase neuroprotection, modulate inflamma-
tion and enhance functional recovery (Zhang et al., 2005; Gerdoni et al., 2007; Bai et 
al., 2009; Barhum et al., 2010; Gordon et al., 2008; Gordon et al., 2010; Kassis et al., 
2008; Kemp et al., 2010; Lanza et al., 2009). The underlying mechanisms are still 
unknown but it might involved one or more of the following possibilities: 1) transdif-
ferentiation of MSCs into functional integrated mature neurons and/or oligodendro-
cytes (MSCs plasticity); 2) bystander effects of MSCs on the survival of damaged 
neurons and / or oligodendroglia 3) bystander effects of MSCs on the fate, and dif-
ferentiation of endogenous NSCs or OPCs present at the lesion site (remyelinista-
tion). 
A number of publications have considered the hypothesis that transplanted adult 
MSCs might transdifferentiate into mature neurons or glial cells, which would inte-
grate into the damaged CNS and promote functional recovery. Although some in vivo 
and in vitro studies indicate that MSCs might transdifferentiate into cells from the 
neural and glial lineage, there is no convincing evidence for the transdifferentiation 
concept, as described above (chapter I.3.2). 
Additionally to the transdifferentiation of MSCs into neuron-like cells, other observa-
tions are discussed to be the source of the potential of MSCs, repairing degenerated 
CNS-tissues. MSCs further promote axonal growth (Neuhuber et al., 2005; Lu et al., 
2005; Hofstetter et al., 2002), reduce axonal loss (Zhang et al., 2006) and reduce the 
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apoptosis of oligodendrocytes (Zhang et al., 2009). In addition to this, the neuropro-
tective effect of transplanted MSCs is endowed with a strong antioxidant effect in vivo 
(Lanza et al., 2009). In summary, transplanted MSCs enhance neuronal and oli-
godendroglial survival. 
MSCs further enhance the proliferation and differentiation of endogenous neural pro-
genitors in vivo and in vitro (Zhang et al., 2004). Regarding the underlying mecha-
nisms, Rivera et al., have recently studied the effects of MSCs on NSCs in vitro and 
demonstrated that soluble factors present in conditioned medium from MSCs (MSC-
CM) strongly activate and promote the oligodendrogenic process in NSCs, as de-
scribed above (Chapter I.4) . 
Other possible mechanisms for the impact of MSC on NSC include the creation of a 
favourable environment for regeneration, expression of growth factors or cytokines, 
vascular effects, remyelinistation or neuroprotection (Parr et al., 2008). It is one pur-
pose of the actual research how these effects of MSCs on NSCs are caused. One 
possibility that this effects are generated through direct cell-cell interactions between 
NSCs and MSCs is analyzed through transplantation experiments. After transplanta-
tion of MSCs after stroke, contusion or penetrating lesions a remarkable recovery 
was detected. In a rat stroke model, after MSCs transplantation a significantly smaller 
volume of damaged tissues was measured and the animals showed a significant 
functional recovery (Le et al., 2005). Indeed, MSCs and NSCs might be close contact 
in vivo; as a result of the dense network of capillaries present, any position in the 
brain is within 50µm to the next capillary. Given that MSCs are found in the circula-
tion, the spacing between MSCs and NSCs might be minimal. Moreover, after CNS 
lesions, the blood-brain barrier becomes leaky and MSCs as well as their secreted 
factors can penetrate the nervous tissue and act locally (Rivera et al., 2006; Munoz-
Elias et al., 2003).  
In summary these data show that MSCs appeared as candidate for brain repair that 
supply large amounts of angiogenetic, antiapoptotic and mitogenic factors to NSPCs, 
as well as migration towards damaged tissue and neural differentiation of them-
selves, although the specific underling mechanisms remain controversial and needs 
to be more explored. 
Although the NSPCs are localized in the same regions in the rat and mouse 
brain, NSPCs seems to be not equal, since they display different properties in re-
sponse to various substrates, mitogenic growth factors like FGF-2 and EGF, heparin 
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and to the influence of differentiation factors on the generation of neurons and glia 
(Ray et al. 2006). It was shown that rNSPCs, cultured in the presence of FGF-2, EGF 
and heparin lost cluster formation and grew as NSph, whereas mNSPCs attached to 
the plates, divided and formed monolayer cultures. Only a small number of spheres 
fails to attach and grows as NSphs. It’s established furthermore that that proliferating 
rNSPCs express mainly glial progenitor markers while mNSPCs more astrocyte/stem 
cell markers. In addition to this, rNSPCs display an oligodendroglial intrinsic fate 
while mNSPCs have mainly an astrocyte intrinsic fate. Moreover rNSCs and mNSCs 
display different electrophysiological properties. mNSPCs showed a resting potential 
(Vrest) that is similar to that of neurons, while rNSPCs had a (Vrest) that is similar to 
that of oligodendrocytes progenitor cells (OPCs) (Steffenhagen et al., 2011). In sum-
mary, these data suggest that rNSPCs mainly display an OPC-like identity, whereas 
mNSPC are composed of a major astrocyte progenitor cell-like population and a mi-
nor neuronal progenitor cell-like population. 
In consistence with these findings, it seems that MSC have a different impact on 
rNSPCs as on mNSPCs. Rivera et al. showed that MSC-CM, as far as the co-culture 
of NSCs and MSCs induces a oligodendrogenic fate decision of differentiating rNSC, 
which was shown through an increase in the percentage of cells expressing the oli-
godendrogenic markers GalC and MBP, as through the enhances expression of the 
oligodendrogenic transcriptional factors Olig1 and Olig2. On the other hand MSC ex-
pense an astroglial differentiation of rNSC, whereas no influence on the neural fate 
decision was detectable (Rivera et al., 2006).  
Consistent with the different cell identity, it looks like that MSC-CM displays different 
effects on adult mNSPCs. Bai et al., analysed if MSCs stimulate the enhancement of 
migration and the survival of neurospheres-derived cells in vitro. It was shown that 
MSCs promote a neural and oligodendrogenic fate decision in adult mNSPCs, again 
with an expense of astrocytes. The data showed that under co-culture of MSCs and 
adult mNSPCs as well as under treatment with MSC-CM a large number of β-tubulin 
positive neurons and O4 positive immature oligodendrocytes was obtained. However 
it was demonstrated in the same paper that the effects of MSCs were mediated 
through soluble factors and were specific for mNSPCs. (Bai et al., 2007).  
These differences could be explained through the differences in nature, chemical 
composition and interactions of a host of intracellular, cell-associated and extracellu-
lar matrix proteins or rat and mouse progenitor cells. 
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II. Aim of the thesis 
 
Adult NSPCs are currently explored for their potential therapeutic use in neuroin-
flammatory and neurodegenerative brain diseases. They can be obtained from differ-
ent areas in the adult CNS and be expanded as NSph culture for several passages in 
vitro. These NSph culture are widely used in the filed and are considered as an in 
vitro model for NSPCs and neurogenesis.  
Considering the fact that mNSPCs and rNSPCs are no homologous cell population 
and that MSCs show different impacts on differentiating mNSPCs and rNSPCs this 
thesis aims to characterize the species-specific effects of MSCs derived soluble fac-
tors on proliferating NSPCs of different rodent species - named mouse and rat. 
First, the influences of MSCs conditioned media (MSC-CM) on proliferating mNSPCs 
and rNSPCs were measured through the morphology changes and the bearing of 
proliferation, cell survival and cell cycle of the NSPCs. Next, the species specific im-
pacts of MSC-CM on proliferating NSPCs were characterized through the phenotype- 
i.e. the expression pattern of specific markers. Third, the cell intrinsic fate (growth 
factor withdrawal response) as well as the differentiation potential of NSPC ware ex-
amined. The obtained effect was confirmed through the expression of the cell fate 
determinants.  
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III. Materials and methods 
 
III.1 Materials 
 
III.1.1. Expendable materials 
 
BD Discardit™ II syringes  Becton Dickinson, Heidelberg 
BD Plastikpak™ syringes (1ml)  Becton Dickinson, Heidelberg 
Cell culture flasks (50ml, 250ml, 500ml)  TPP, Switzerland 
 Greiner Bio-One GmbH, Frickenhausen 
Combitips  Eppendorf, Hamburg 
Cover glasses Menzel (∅13mm)  VWR, Darmstadt 
Cryo Tubes  Nunc, Denmark 
Disposable gloves  Hartman, Heidenheim 
 Semperit Austria 
Microscope slides  Menzel GmbH & Co KG, Braunschweig 
Pipette tips  Sarstedt, Nürmbrecht 
Pipette tips with filter  Biozym, Hessisch Oldendorf 
Syringe-Filter (0.22µm)  TPP, Switzerland 
 Millipore, USA 
Test plates (24-well, 96-well)  Omnilab, Schubert & Weiß, München 
 TPP, Switzerland 
Tubes  Eppendorf, Hamburg 
 Falcon BD, Heidelberg 
 Gibco BRL, Karlsruhe 
 Sarstedt, Nümbrecht 
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III.1.2. Reagents and media for cell culture 
 
a.) Neurobasal (NB) NSph proliferation media 
 
Neurobasal Media  Gibco, Karlsruhe 
100 µg/ml Penicillin/Streptomycin  PAN Biotech GmbH, Aidenbach 
200 mM L-Glutamin  PAN Biotech GmbH, Aidenbach 
1x B27-Supplement  Gibco BRL, Karlsruhe 
20 ng/ml Fibroblast Growth Factor (FGF)  R&D Systems, Wiesbaden-Nordenstadt 
20 ng/ml Epidermal Growth Factor (EGF)  R&D Systems, Wiesbaden-Nordenstadt 
2 µg/ml Heparin  Sigma-Aldrich, Taufkirchen 
 
b.) α-Modified Eagle Media (MEM) MSC – proliferation media 
 
α-MEM  Gibco, Karlsruhe 
100 µg/ml Penicillin/Streptomycin  PAN Biotech GmbH, Aidenbach 
10% Fetal bovine serum (FBS)  PAN Biotech GmbH, Aidenbach 
 
c.) Knockout- Dulbecco’s Modified Eagle Media (DMEM) NSph - differentiation media 
without serum 
 
Knockout-DMEM Media  Gibco Invitrogen, Karlsruhe 
100 µg/ml Penicillin/Streptomycin  PAN Biotech GmbH, Aidenbach 
200 mM Glutamin  PAN Biotech GmbH, Aidenbach 
20% Serum Replacement (SR)  Gibco, Karlsruhe 
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III.1.3. Other reagents for cell culture 
 
Accutase PAA,  Pasching, Austria 
Dulbecco’s PBS  Gibco, Karlsruhe 
Laminin  Sigma-Aldrich, Taufkirchen 
Poly-L-Ornithin  Sigma-Aldrich, Taufkirchen 
Trypanblue  Sigma-Aldrich, Taufkirchen 
Trypsin-EDTA solution  Gibco Invitrogen, Karlsruhe 
 
III.1.4. Kits & master mix 
 
Cytotox 96® Non-radioaktive Assay Promega, Wisconsin USA 
FITC-conjugated antibody set (Ki67) BD Biosciences Pharmigen, San Diego 
USA 
PCR-Kit RNeasy Mini kit Quiagen, Hilden 
Reverse transcription Kit Promega, Wisconsin USA 
TagMan Applied Biosystems, California, USA 
 
III.1.5. Other chemicals and reagents 
 
Agarose Invitrogen, Karlsruhe 
Bovine Serum Albumine (BSA)  Sigma-Aldrich, Taufkirchen 
1-bromo-3-chloropropane (BCP)  Sigma-Aldrich, Taufkirchen 
Bromphenol Blue  Sigma-Aldrich, Taufkirchen 
DNase I  Quiagen, Hilden 
Ethanol  Merck-Schuchard, Hohenbrunn 
Ethidiumbromide  Sigma-Aldrich, Taufkirchen 
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Fish Skin Gelatine  Sigma-Aldrich, Taufkirchen 
Glycerol  AppliChem, Darmstadt 
HCl  Merck, Darmstadt 
Mercaptoethanol Sigma-Aldrich, Taufkirchen 
Paraformaldehyde (PFA)  Sigma-Aldrich, Taufkirchen 
PCR marker  NEB, Frankfurt 
Phosphate buffered saline (PBS)  PAA, Pasching, Austria 
Prolong Anti Fade reagent  Invitrogen Molecular Probes™ Eugene, 
 Oregon, USA 
Propidium-iodite Sigma-Aldrich, Taufkirchen 
RNase A Roche Diagnostics  
Sodium hydrogen carbonate  Merck, Darmstadt 
Tris-Base  Sigma-Aldrich, Taufkirchen 
Triton 100-X  Sigma-Aldrich, Taufkirchen 
 
 
 
III.1.6. Buffer, solutions and stock solutions 
 
a.) Fish Skin Gelatin Buffer (FSGB)  0.1M Tris-HCl, pH 7.5 
 0.15M NaCl 
 1% w/v BSA 
 0.2% v/v Fish Skin Gelatin 
 Optional: 0.1% v/v Triton X-100 
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b.) 4% Paraformaldehyde (PFA)  4% PFA 
 2.5mM NaOH 
 0.4mM CaCl2 
 50mM Sucrose 
 0.1M NaH2PO4 
 
III.1.7. Devices 
 
Device  Company 
Centrifuge 5417 R  Eppendorf, Hamburg 
E-Max precision microplate reader Molecular Device Corporation, USA 
FACSCalibur Becton Dickinson 
Fluorescence Microscope Leica DMR Leica, Solms Diagnostic Instruments, 
with SPOT Camera USA 
Incubator  HERA Cell 
Inverse Fluorescence microscope Olympus, Hamburg 
Light microscope Olympus CK 30  Olympus, Hamburg 
Megafuge 1.0 R  Heraeus Instruments GmbH, Germany 
Olympus IX 70 with Color View Soft Imaging Systems, Münster 
documentation system 
Photometer Ultrospec 2000  Amersham/Pharmacia Biotech, Freiburg 
Rotor-Gene 6000 R Corbett Research  geneXpress, Vienna, Austria 
 
III.1.8. Software 
 
Adobe PhotoshopC2 Version 9.0  Adobe Systems GmbH, München 
EndNote 7  Thompson ResearchSoft, USA 
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GraphPad Prism  GraphPad Software Inc., USA 
Microsoft Office  Microsoft Corporation 
Softmax. Version 2.34 Molecular Device Corporation, USA 
WinMDI2.8 Microsoft Corporation 
 
III.2. Cell culture methods 
 
III.2.1. MSC cultures 
 
Six to eight week old female Fisher rats were killed by cervical dislocation. Femurs 
and tibias were obtained from the legs after the muscular tissue was removed. Bone 
marrow plugs harvested from femur and tibia were resuspended in approximately 
10ml of α-MEM, desegregated, homogenized and recovered by centrifugation (800 x 
g). The resulting cell pellet was resuspended in α-MEM containing 10% FBS (α-
MEM- 10%FBS). The cell number was determined by Trypan blue exclusion and the 
cells were seeded at 1x106 cells/cm2 into 56 cm2 culture dishes in the following. Cells 
were incubated in a humidified incubator at 37°C wi th 5% CO2. After three days, non-
adherent cells were washed off and adherent cells were further incubated in fresh α-
MEM-10%FBS until a confluent layer of cells was reached. Afterwards, cells were 
trypsinized using a 0,25% Trypsin-EDTA solution, resuspended in α-MEM-10%FBS 
and seeded at a density of 8000 cells/cm2. After three to five days, the resulting 
monolayer of cells was again trypsinized and frozen or further cultured for experi-
ments (Santa Maria et al., 2004). 
 
III.2.2. Preparation of NSCs primary cultures 
 
Six to eight week old female Fisher rats and C57BL/6 (Charles River Deutschland 
GmbH, Germany) mice were anesthetized with ketamine and decapitated. Brains 
were removed and collected in ice cold Dulbecco’s PBS (DPBS). HC and SVZ were 
taken out. To remove the PBS brain pieces were centrifuged for 5 minutes at 120 x g 
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at 4°C. Then, the dissected tissue was mechanically  dissociated with a razor blade. 
In order to wash the tissue with PBS it was transferred back into the tube, PBS was 
added and it was centrifuged again for 5 min at 120 x g and 4°C. The pellet was re-
suspended in 10 ml PPD-solution containing 0,01% Papain, 0,1% dispase II, 0,01% 
DNase I and 12,4 mM MgSO4 in HBSS without Mg2+/Ca2+. Cells were digested for 30 
to 40 minutes in the PPDsolution, triturating every 10 min. After further centrifugation 
like mentioned before, supernatant was removed. The pellet was resuspended in 
serum-free Neurobasal media (NB) containing B27-supplement, 2 mM L-glutamine 
and 100 U/ml penicillin/ 0,1 mg/l streptomycin and cells were centrifuged again. This 
step was repeated once more. At the end the pellet was resuspended in NB media 
supplemented with B27-supplement, 2 mM L-glutamine, 100 U/ml penicillin/ 0,1 mg/l 
streptomycin, 2 µg/ml heparin, 20 ng/ml EGF and 20 ng/ml FGF. Cells were plated 
into T-25 culture flasks and maintained at 37°C in a humidified incubator with 5% 
CO2 . 
 
III.2.3. Cultivation and passaging of adult NSCs 
 
NSCs were cultured in T-75 cell culture flasks with a density of 5 x 104 cells/ml in NB 
media. Media were changed 3-4 days after seeding. To passage the NSph, the cul-
ture media containing the floating NSph was collected in a 15 ml tube and centri-
fuged at 120 x g for 5 min. For dissociation, the pellet was resuspended in 200 µl Ac-
cutase and triturated using a pipette tip. The cell suspension was incubated at 37°C 
for 10 min in the water-bath. To stop the Accutase reaction 0.8 ml media were added 
and the cells were dissociated mechanically by aspirating and expelling the suspen-
sion with a pipette. Cell number was determined by Trypan blue exclusion and 5 x 
104 cells/ml were plated in new T-75 culture flasks in NB media. NSPCs used in this 
study were derived from cultures of passage number four to eight. 
 
III.2.4. Cell counting 
 
For estimating proliferation of NSphs by assessing cell number, 5 x 104 cells were 
seeded in T75 cell culture flasks either with Neurobasal medium, or with a mixture 
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50% Neurobasal medium and 50% MSC-CM (50% MSC-CM), or only with MSC-CM 
(100% MSC-CM). The cells were cultivated in these mediums and were determined 
by Trypan blue exclusion after 7, 14 and 21 days. Media were changed after three to 
four days. 
 
III.2.5. Preparation of MSC-conditioned media 
 
Mesenchymal stem cell conditioned medium (MSC-CM) was prepared similar as de-
scribed in Rivera et al., 2006 with the exception of the media used. MSCs were 
plated at 12,000 cells/cm2 and incubated in normal NSCs proliferation medium (NB 
medium supplemented with B27 (NB/B27), 2 mM L-glutamine, 100U/mL penicillin/ 
100 µg/ml streptomycin, 2 µg/ml heparin, human recombinant 20 ng/ml bFGF-2 and 
human recombinant EGF 20 ng/ml). After 3 days, the conditioned medium was col-
lected and filtered using a 0.22 µm-pore filter. In some of the experiments, the condi-
tioned medium was replenished with EGF and b-FGF (20 ng/ml each) to exclude the 
possibility that MSCs might have consumed the growth factors.  
 
III.2.6. Coating of coverslips with poly-L-ornithin and laminin 
 
Glass-coverslips (13 mm) (Menzel GmbH, Braunschweig, Germany) were incubated 
in 1 M HCl at 65°C overnight and stored in isopropa nol until further use. Coverslips 
were put into 24-well test plates and air-dried. Coverslips were incubated for at least 
2 h with 100 µg/ml Poly- L-ornithin solution at 37°C in the follo wing. After washing 
three times with sterile water coverslips were incubated with 5 µg/ml laminin solution 
for 2 h. Immediately after removal of the laminin solution cells were seeded. 
 
III.2.7. Phenotype and fate analysis of NSph 
 
To assess the potential of various factors to change phenotype and fate of adult 
rNSph and mNSph cells were incubated for three weeks under proliferation condi-
tions (NB-Medium [Control], 50% MSC-CM and 100% MSC-CM. Media were 
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changed every three to four days and after seven days the NSph cultures were pas-
saged like mentioned before (s. II.2.3.) After three weeks of incubation, 2-5 x 104 
cells/well were plated on poly-L-ornithine (100 µg/ml) and laminin (5 µg/ml)- coated 
glass coverslips (s. II.2.6.) into 24-well plates in DMEM Knockout-20% SR. After 12 
h, cells were either directly fixed for 30 min with 4% Paraformaldehyde and proc-
essed for immunofluorescence staining or media was refreshed for further incubation 
of the cells. After 7 days, the remaining cells were fixed for 30 min with 4% Parafor-
maldehyde and processed for immunofluorescence staining. 
 
III.2.8. Immunofluorescence analysis and quantification 
 
First, the fixed cells were washed three times in Phosphate-buffered saline (PBS) 
and then blocked with Fish Skin Gelatin Buffer (FSGB) to occupy unspecific binding 
sites for 2 h at room temperature. If staining should be performed for a cyctoplasmic 
marker the use of FSGB containing 0.1% Triton X-100 was necessary in order to 
make the cell membrane permeable for the antibody. The same blocking solution 
was also used for the dilutions of the antibodies. The primary antibodies were applied 
overnight at 4°C.  
The following antibodies and dilutions were used: 
 
a.) Primary Antibodies 
Primary Antibodies Dilution Company 
rabbit anti-NG2 1:200 Millipore, USA 
IgM mouse anti-O4  1:100  Chemicon, USA 
IgM mouse anti-A2B5 1:100  Chemicon, USA 
rabbit anti-platelet-derived  
growth factor receptor 
(PDGFRα) 
1:100 Santa Cruz, Heidelberg 
IgM mouse anti-polysialylated- 
neural-cell-adhesions-molecule 
(PSA-NCAM) 
1:500 Millipore, USA 
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rabbit anti-glial fibrillary acidic protein  
(GFAP)  
1:1000 Dako, Glostrup, Denmark 
mouse anti-myelin basic protein  
(MBP) (SMI94) 
1:750 Hiss- Freiburg 
rabbit anti-doublecortin (DCX)  1:500  NEB, Frankfurt 
mouse anti-rat nestin  1:500  Pharmingen, Heidelberg 
mouse anti 2’, 3’-cyclic-nucleotide- 
3’-phosphodieesterase (CNPase) 
1:200 Millipore, USA 
mouse anti-microtuble-associated- 
protein 2a+b (Map2a+b) 
1:400 Sigma-Aldrich, Taufkirchen 
Table 1 Primary antibodies used 
 
After washing three times with FSGB, cells were incubated with the species-specific 
secondary antibodies, which were conjugated to fluorochromes, for 2 h in the dark at 
room temperature. The following antibodies and dilutions were used: 
 
b.) Secondary Antibodies 
 
Secondary Antibodies Dilution Company 
donkey anti-mouse, -rabbit 
conjugated with rhodamine X  
(RHOX); IgG and Ig M 
1: 500 Dianova, Hamburg 
donkey anti-mouse, -rabbit 
conjugated with Alexa Fluor®$488 
1:1000 Invitrogen Molecular Probes, 
Eugene, Oregon USA 
Table 2 Secondary antibodies used 
 
To remove unbound secondary antibodies, cells were washed again with PBS. The 
cell nuclei were counterstained with 4’, 6’-diamidino-2-phenylindole dihydrochloride 
hydrate (DAPI) at 0,25 µg/µl diluted in PBS. Finally, cells were washed again three 
times with PBS and were mounted on microscope slides using Prolong Antifade re-
agent. 
For the simultaneous detection of two different antigens the used primary and secon-
dary antibodies were incubated simultaneously. For analysis and quantification, epif-
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luorescence was observed via a Leica microscope and documented by a coupled 
Spot digital camera. Three to seven observation fields were selected randomly and 
photographed for cell fate analysis. 
 
III.2.9 FACS analysis (Ki67)  
 
mNSCs were incubated with NB-Medium (Control), 50% MSC-CM and 100% MSC-
CM under normal proliferative conditions for 7, 14 and 21 days. After the accordant 
days the cells were dissociated into single cells with Accutase. After 10 min incuba-
tion at 37°C, Accutase was exhausted and cells were  resuspended in 1 ml of ice-cold 
70% ethanol. They were kept overnight at -20°C.  At the earliest one day later, cells 
were processed for staining according to a protocol of Endl (Endl et al., 1997) which 
was slightly modified. At first, 2 ml of ice-cold PBS were added to each sample. Cells 
were centrifuged (600 x g for 5 min), resuspended in 500 µl ice-cold PBS containing 
0.1% Triton X-100 and incubated for 5 min on ice. Cells were washed twice by add-
ing 2 ml of ice-cold PBS followed by centrifugation for 5 min at 600 x g. Pellets were 
then resuspended in 120 µl PBS containing either FITC conjugated mouse anti-
human Ki67 or mouse IgG control antibody (100 µl PBS+20 µl antibody solution) and 
incubated at room temperature for 30 to 45 min in the dark. Afterwards samples were 
washed by adding 1 ml of PBS. They were centrifuged, supernatant was aspirated 
and cells were resuspended in 470 µl of PBS and 5 µl of RNase A (stock 1 mg/ml). 
After a 60-minute incubation at 37°C, 25 µL of prop idium-iodide (stock 1 mg/ml) were 
added and samples were analyzed on a FACSCalibur flow cytometer. Data were 
processed using WinMDI 2.8 software. 
 
III.2.10 CytoTox96®Non-Radioactive Cytotoxicity Assay  
 
mNSCs were incubated with NB-Medium (Control), 50% MSC-CM and 100% MSC-
CM under proliferative conditions for 7, 14 and 21 days. After the accordant days the 
cells were centrifuged at 240 x g for 5 min. Aliquots of 50 µl from all tubes were car-
ried over a fresh 96-well plate and 50 µl substrate mix were added to each well of the 
plate. Cells were incubated at room temperature for 30 min under protection from 
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light. Subsequently 50 µl of stop solution were added to each well before the absorb-
ance was recorded at 490 nm. 
 
III.3 Molecular Methods 
 
III.3.1. RNA – Extraction from Neurospheres  
 
RNA extraction from adult NSph was performed using RNeasy Mini Kit (Qiagen, Hil-
den, Germany). Cells were spun down and the pellet was lysed in RLT buffer sup-
plemented with 0,1 M 2-Mercaptoethanol (1:100 dilution). The lysate was homoge-
nized by aspirating and expelling the suspension with a pipette vigorously. The ho-
mogenate was mixed with 350 µl 70% Ethanol and was loaded onto the RNeasy spin 
column by centrifugation at 10000 x g for 1 min. After washing the sample with 350 µl 
RW1 buffer and centrifugation at 10000 x g for 1 min, DNA digestion was performed 
in order to remove genomic DNA contamination. For that, a mixture of 10 µl DNase I 
and 70 µl RDD buffer (Qiagen, Hilden) was added to each column and incubated for 
15 min at room temperature. After the incubation, columns were washed again with 
350 µl RW1 buffer to remove the DNase. 
Afterwards, columns were washed with RW1- and RPE buffer followed by centrifuga-
tion at 10000 x g for 1 min to get rid of contaminations of the RNA. To dry the silica 
gel membrane columns were placed into new 2 ml collection tubes and centrifuged at 
10000 x g for 2 min. Finally, RNA was eluted by adding 30 µl of RNase free water to 
the columns and centrifuging at 10000 x g for 1 min. To get a higher concentration of 
RNA the elution step was repeated using the eluate from the step before. 
For determination of RNA concentration, the RNA was diluted with H2O (1:25) and 
the absorbance was measured with a photometer. RNA was stored at -80°C until 
cDNA synthesis was performed. 
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III.3.2 cDNA synthesis 
 
cDNA synthesis was performed using Promega reverse transcription Kit. 1 µg of RNA 
was used for the reverse transcription into cDNA. The sample was filled up to a vol-
ume of 9 µl with RNase free H2O. The mixture was put into the thermocycler (Ep-
pendorf, Hamburg) for 10 minutes at 70°C. While on 4°C for 10 minutes 11 µl of the 
Master Mix were added. The  
 
Master Mix contained: 
 
4 µl MgCl2 (4 mM) 
2 µl dNTP (800 µM) 
2 µl Reverse Transcription 10 x buffer (100 mM Tris-HCl, (pH 8.8); 500 mM 
KCl, 
1% Triton X-100) 
1 µl Random Primers (20 ng/µl) 
0.7 µl AMV Reverse Transcriptase (5 U/ml) 
0.5 µl RNase Inhibitor (40 U/ml) 
0.8 µl H2O 
Σ 11 µl 
 
After adding the master mix the temperature profile was the following: 
 
10 min 21°C 1x 
15 min 42°C 1x 
05 min 95°C 1x 
05 min  4°C 1x 
 
The final cDNA equivalent concentration was 50 ng/µl (1 µg/20 µl). cDNA was stored 
at -20°C. 
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III.3.2 Quantitative PCR 
 
Expression analysis was performed by TaqMan gene expression assays kits (Applied 
Biosystems, California, USA) for the following rat genes: olig2 and Id2. Probes and 
primers were provided by the manufacturer (Applied Biosystems, California, USA). 
Rat β2-microglobulin was used as endogenous normalized gene. The following tem-
perature profile was used: activation of polymerase 95 C, 10 min; 40 cycles of dena-
turing 95 C, 15 s, and annealing/extension 60 C, 60 s. Data was obtained with a Ro-
tor-Gene 6000 R Corbett Research (geneXpress, Vienna, Austria) and analyzed by 
delta delta Ct method (Livak and Schmittgen, 2001). Gene expression under control 
conditions was used as a calibrator gene. Finally, the expression value of Olig2 and 
Id2 was determined for each condition. To determine the Olig2/Id2 ratio, Id2 was 
used as a calibrator gene for each condition.  
 
III.3.3 Gel electrophoresis of DNA 
 
Separation of DNA fragments was performed via Agarose gel electrophoresis (1,5 % 
Agarose in TBE). Additionally to the DNA a DNA ladder was applied to determine the 
size of the DNA fragments after the electrophoresis. Electrophoresis occurred at the 
constant voltage of 96V. The Agarose gel was supplemented with an Ethidiumbro-
mide solution which intercalated into the DNA so that the DNA fragments could be 
detected under UV-light. 
 
III.4. Statistics  
 
Data are presented as means ± SD and statistical analysis was performed using 
PRISM4 (GraphPad, San Diego, CA, USA). P values of < 0,05 were considered to be 
significant acquired by parametric one-way ANOVA-Tukey post hoc. All experiments 
were performed in triplicate or more.   
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IV. Results  
 
MSCs have been demonstrated to promote functional recovery in a number of neuro-
logical diseases in animal models (f.e. Lee et al. 2008). In the respect it was shown 
that soluble factors derived from MSCs induce an oligodendrocyte fate on adult 
NSCs under serum containing conditions (Rivera et al., 2006). Here, we test the hy-
pothesis that MSCs produce soluble factors that might influence the biology of neural 
stem/progenitor cells undergoing proliferation. To reach this reason we performed all 
experiments in serum free conditions, to get the cells in proliferation.  
The effects of MSC-CM on proliferating adult rNSph and mNSph were ana-
lyzed regarding cell morphology, proliferation, survival, cell cycle, cell phenotype (cell 
specific marker and cell fate determinant expression profile) and growth factor with-
drawal response. 
 
IV.1. Effects of MSC-CM on proliferating rNSphs  
 
IV.1.1. MSC-CM promotes adhesion of proliferating rNSphs and affects 
cell morphology  
 
MSC-CM was used to study the effect of soluble factors derived from MSCs on pro-
liferating rNSphs. rNSphs were incubated under normal proliferating conditions (con-
trol), 50% MSC-CM or 100% MSC-CM. After 7, 14 or 21 days cell morphology was 
analyzed at the Olympus microscope. Proliferating rNSphs grew as floating aggre-
gates, when they were cultured in normal proliferating medium (control) (figure1 A, D, 
G). However, when rNSphs were incubated with 50%MSC CM or 100% MSC-CM, 
they started to attach to the plate and primary and secondary process were observed 
independently from incubation time (figure 4 B, C, E, F, H, I). 
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Figure 4. Morphology of proliferating rNSphs. 
Phase contrast images of rNSphs in normal proliferation medium (control) (A,D,G); treated with 50% 
MSC-CM medium (B,E,H) or with 100% MSC-CM (C,F,I). Proliferating rNSphs were incubated during 
7 days (A-C), 14 days (D-F) and 21 days (G-I). Note that under control conditions proliferating rNSphs 
grew as floating aggregates, however when the cells were treated with 50% or 100% MSC-CM some 
rNSphs attached to the surface of the flask and grew adherent . Scale bar = 100 µm. 
 
IV.1.2. MSC-CM has no effect on the absolute number of rNSphs in vitro 
 
To detect any influence of MSC-CM on the growth characteristics of proliferating 
rNSphs, cells were incubated under normal proliferating conditions (control), 50% 
MSC-CM or 100% MSC-CM for 21days with a change of media every 3-4 days. After 
7, 14 and 21 days cell number was analyzed by Trypanblue exclusion.  
The cells grew exponentially after seeding, equal which media were used (control, 
50% MSC-CM or 100% MSC-CM). It was not possible to detect any significant differ-
ence in the absolute number of cells nor any significant difference in the kinetics be-
tween the three media (figure 5 A, B, C).  
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These data indicated that MSC-CM has no detectable influence on the prolif-
eration of proliferating rNSphs. 
 
Figure 5. MSC-CM has not any significant influence on the growth-bearing of proliferating 
rNSphs. 
rNSphs were incubated in normal proliferation medium (control), 50% MSC-CM and 100% MSC-CM, 
to check the influence of MSC-CM on the proliferation of proliferating rNSphs. Cell number was ana-
lyzed by Trypanblue exclusion after 7, 14 and 21 days. It was not possible to detect any significant 
difference in the growth-bearing and the proliferation rate of proliferating rNSphs. These data indicated 
that MSC-CM has no detectable influence on the proliferation of proliferating rNSphs. 
 
IV.1.3. MSC-CM does not affect the highly expression pattern of glial and 
oligodendroglial progenitor markers on proliferating rNSphs  
 
To determine whether MSC-CM affects the expression pattern of cell lineage specific 
markers, non-treated (control) and MSC-CM-treated proliferating rNSphs were disso-
ciated. After dissociation single cells were seeded overnight under serum-free condi-
tions to allow them to attach. After this procedure cells were fixed and marker ex-
pression was analyzed in the following.  
Most of the cells derived from proliferating control rNSphs expressed the oligoden-
droglial progenitor marker O4 (approximately 90% figure 6 G, H), the glial progenitor 
markers A2B5 (approximately 50% figure 6 C, D) and NG2 (approximately 30% fig-
ure 6 E, F). MSC-CM-treated proliferating rNSphs displayed no difference on the per-
centage of cells that express glial and oligodendroglial progenitor markers compared 
to non-treated proliferating rNSphs (figure 6 D, F, H). In addition to this, a small sub-
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population of cells derived from proliferating rNSphs expressed astrocyte/neural stem 
cell markers GFAP and Nestin (between 5 to 15% figure 6 A, B). MSC-CM treatment 
seemed to not affect the expression of the astrocyte/neural stem cell phenotype with 
the exception on the percentage of GFAP-expressing cells. There a slightly increase 
was detected (Fig 6 B). Finally, there were few cells that express the neuronal pro-
genitor marker DCX on normal proliferating rNSphs (less than 2% figure 6 I, J). MSC-
CM treatment did not affect the DCX expression (figure 6 J).  
In summary these findings suggested that soluble factors derived from MSCs 
did not affect the major expression pattern of glial and oligodendroglial markers on 
proliferating rNSphs. 
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Figure 6. Marker expression profile of proliferating rNSphs pre-incubated 21 days under control 
condition, 50% MSC-CM and 100% MSC-CM. 
Treated rNSphs were dissociated and cells were seeded overnight under serum-free conditions. One 
day after the cells were fixed and stained for immunohistochemistry. The marker expression was ana-
lyzed by immunofluorescence. Illustrative fluorescence images are shown for Nestin (red), GFAP 
(green) and DAPI (blue) (A); A2B5 (red) and DAPI (blue) (C); NG2 (green) and DAPI (blue) (E); O4 
(red) and DAPI (G); and DCX (green) and DAPI (blue) (I). Quantitative analysis for each marker are 
shown (B, D, F, H and J). Note that there was no significant change between the different conditions 
for any marker tested with the exception of GFAP. * = p<0.05; ** = p<0.01; *** = p<0.001. Scale bar = 
100µm 
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IV.1.4. MSC-CM enhances rNSphs oligodendrogenic response after 
growth factor withdrawal  
 
In a previous study it was illustrated that rNSphs spontaneously differentiate into oli-
godendrocytes after GFW (Steffenhagen et al., 2011). To determine whether MSC-
CM affects this oligodendrogenic response after GFW, non-treated and MSC-CM-
treated proliferating rNSphs were dissociated and seeded overnight under serum-
free conditions and incubated for 7 days without growth factors (FGF-2 and EGF).  
As expected, one week after GFW, dissociated non-treated rNSphs spontaneously 
differentiate into mature oligodendrocytes since approximately 60% of the cells of the 
control group expressed the oligodendrocyte mature marker MBP (figure 7 G, H). 
Interestingly, although MSC-CM treatment on proliferating rNSphs did not affect the 
proportion of O4-expressing oligodendrocyte progenitor cells (figure 7 C, D) it in-
creased the percentage of CNPase- and MBP-expressing mature oligodendrocytes 
in response to GFW (figure 7 E, F and G, H respectively).  
It was not possible to observe a difference on the percentage of cells that display 
astrocyte/neural stem cell phenotype on MSC-CM-treated rNSphs compare to con-
trol, since Nestin and GFAP expression was not affected after GFW (figure 7 A, B). 
Finally, there were few cells that expressed the neuronal progenitor marker DCX in 
response to GFW (less than 4% figure 7 I, J) and MSC-CM treatment on proliferating 
rNSphs decreased the percentage of DCX expressing cells (figure 7 J) but did not 
affect the proportion of Map2ab-positive mature neurons generated after GFW (less 
then 1% figure 7 K, L).  
In summary, these data support that MSC-CM enhances the oligodendrogenic 
ability of proliferating rNSphs in response to GFW.  
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Figure 7. Growth factor withdrawal response of rNSphs pre-incubated 21 days under control 
condition, 50% MSC-CM and 100% MSC-CM.  
Treated rNSphs were dissociated, seeded and incubated for one week under serum-free conditions 
without growth factors. After 21 days cells were fixed and stained for immunohistochemistry. Marker 
expression was analyzed by immunofluorescence. Illustrative fluorescence images are shown for 
Nestin (red), GFAP (green) and DAPI (blue) (A); O4 (red) and DAPI (blue) (C); CNPase (red) and 
DAPI (blue) (E); MBP (red) and DAPI (G); DCX (green) and DAPI (blue) (I); and MAP2ab (red) and 
DAPI (blue) (K). Quantitative analyses for each marker are shown in the left panels (B, D, F, H, J and 
L). Note the significant increase in the percentage of cells that express the oligodendroglial markers 
CNPase and MBP when cells were pre-incubated with 50% and 100% MSC-CM compared with the 
control condition. There is also a significant decrease in the percentage of cells that express the neu-
ronal marker DCX in 50%MSC-CM and 100% MSC-CM compared with the control medium. * = 
p<0.05; ** = p<0.01; *** = p<0.001. Scale bar = 100µm 
 
IV.1.5. MSC-CM primed the oligodendrogenic program on proliferating 
rNSphs 
 
First in order to verify if proliferating rNSphs response to GFW activating an oli-
godendrocyte differentiation program, the expression pattern of oligodendrogenic 
markers on proliferating rNSphs and one week after GFW has been compared.  
The expression pattern of the glial progenitor markers A2B5 (figure 8 A, from ap-
proximately 60% to less than 5%) and PDGFα (figure 8 B, from approximately 30% 
to less than 5%) were drastically reduced, while the oligodendrocyte mature marker 
MBP was significant increased in response to GFW (figure 8 F, from less than 5% to 
approximately 60%). In addition, the high expression of the oligodendrocyte progeni-
tor and immature marker O4 was maintained after GFW (figure 8 D). These observa-
tions suggest an activation of an oligodendrocyte differentiation program in response 
to GFW, in which the expression of early oligodendrogenic markers switch-off while 
late markers switch-on. MSC-CM-treated proliferating rNSphs displayed a higher ca-
pacity to switch-off the glial progenitor marker NG2 after GFW compared to non-
treated proliferating rNSphs (figure 8 C). Moreover, as was previously mentioned 
MSC-CM treatment increased the percentage of CNPase- and MBP-expressing cells 
in response to GFW compared to control conditions (figure 8 E, F). In addition to this, 
  
 
IV. RESULTS - 39 -
 
MSC-CM treatment seemed to increase also the percentage of MBP-expressing cells 
under proliferative conditions respect to control (figure 8 F).  
In conclusion, these data suggest that soluble factors derived from MSCs pre-
dispose or prime the oligodendrogenic program of proliferating rNSphs and therefore 
enhancing oligodendrogenesis.  
In a further trial of experiments, it was tested if oligodendroglial priming of pro-
liferating rNSphs by MSC-CM could induce an altered expression of pro- and anti-
oligodendrogenic fate determinants. Here, the relative expression of Olig2 and Id2 is 
a key determinant for oligodendrocyte / astrocyte fate decision. Therefore, proliferat-
ing rNSphs were incubated up to 3 weeks under normal proliferating conditions (con-
trol), 50% and 100% MSC-CM, the expression levels of Olig2 and Id2 were analyzed 
by quantitative RT-PCR and the Olig2/Id2 ration was determined for the different 
conditions. Although the expression levels of Olig2 did not change within the different 
conditions (figure 8 A), 50% and 100% MSC-CM drastically reduced the expression 
of Id2 (figure 8 B). In consistence, MSC-CM increased the Olig2/Id2 ratio compared 
to control conditions (figure 8 C) favouring oligodendrocyte fate decision. Moreover, 
the increased Olig2/Id2 ratio in MSC-CM-treated rNSphs might explain the higher 
oligodendrogenic response to GFW compared to non-treated rNSphs. In conclusion, 
these data announce that soluble factors derived from MSCs prime proliferating 
rNSphs to oligodendrogenesis. 
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Figure 8. Effects of MSC-CM on the oligodendrogenic capacity of proliferating rNSphs. 
Pre-incubated rNSphs were dissociated and seeded overnight under serum-free conditions. Then cells 
were either fixed to analyze the marker expression profile under proliferative conditions or either were 
incubated in the absence of growth factors up to 7 days and fixed to analyze the growth factor re-
sponse. Immunofluorescence was performed for the different markers of the oligodendrogenic pro-
gression (early and middle and late). Quantitative marker expression of A2B5 (A), PDGFRα (B), NG2 
(C), O4 (D), CNPase (E) and MBP (F). Note that after growth factor withdrawal cells showed a de-
crease in the expression of oligodendrocyte progenitor markers (A2B5, PDGFRa, NG2) and an in-
crease in the expression of the mature oligodendrocyte marker MBP. Observe that rNSphs pre-
incubated with MSC-CM display more MBP- and CNPase- expressing cells than control conditions 
after growth factor withdrawal. * = p<0.05; ** = p<0.01; *** = p<0.001 
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IV. 2. Effects of MSC-CM on proliferating mNSphs  
 
IV.2.1. MSC-CM promotes proliferating mNSphs adhesion affecting cell 
morphology 
 
In a second part of experiments we wanted to examine the effect of soluble factors, 
driven from MSCs on proliferating mNSphs. mNSphs have different properties in at-
tachment, response to growth-factors etc. compared to rNSphs as mentioned in the 
introduction before (Ray et. al. 2006). For the following experiments MSC-CM was 
used again as described in III.2.5. mNSphs were incubated under normal proliferat-
ing conditions (control), 50% MSC-CM or 100% MSC-CM. After 7, 14 or 21 days cell 
morphology was analyzed at the Olympus microscope. 
Proliferating mNSphs grew mainly attached on the plate, only some mNSphs grew as 
floating aggregates, when the cells grew under normal proliferation conditions (con-
trol) (figure 9 A, D, G). Proliferating mNSphs, exposed to 50% MSC-CM and 100% 
MSC-CM displayed a less sphere formation than in the control condition, independ-
ent of incubation time (figure 9 B, C, E, F, H, I). 
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Figure 9. Morphology of proliferating mNSphs. 
Phase contrast images of mNSphs in normal proliferation medium (control) (A,D,G); treated with 50% 
MSC-CM medium (B,E,H) or with 100% MSC-CM (C,F,I). Proliferating mNSphs were incubated during 
7 days (A-C), 14 days (D-F) and 21 days (G-I). Note that independent of the incubation time proliferat-
ing mNSphs exposed to 100% MSC-CM displayed less sphere formation than control condition. Scale 
bar = 100 µm 
 
IV.2.2 MSC-CM treatment decreases the absolute number of mNSphs in 
vitro 
 
As mentioned above mNSphs displayed a less sphere formation under treatment 
with 50% MSC-CM and 100% MSC-CM. To check if these decrease in sphere forma-
tion was caused by a decrease of cell number, mNSphs were incubated under nor-
mal proliferating conditions (control), 50% MSC-CM or 100% MSC-CM. After 7, 14 
and 21 days cell number was analyzed by Trypan blue exclusion. 
As expected the percentage of 50% MSC-CM and 100% MSC-CM treated cells was 
significant lower compared to the control, 21 days after seeding (approximately 90% 
figure 10 A, B).  
The obtained growth curve showed the difference of the growth rate of MSC-CM and 
not MSC-CM treated cells. Not treated control cells showed an exponential growth 
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curve, whereas 50% MSC-CM and 100% MSC-CM showed a final plateau, after a 
small expansion phase.  
In summary these data exhibited that treatment with 50% MSC-CM and 100% 
MSC-CM decreases the absolute cell number of proliferating mNSphs.  
 
Figure 10. MSC-CM treatment decreases the absolute cell-number of mNSphs in vitro. 
mNSphs were incubated in normal proliferation medium (control), 50% MSC-CM and 100% MSC- CM, 
to check the influence of MSC-CM on the proliferation of proliferating mNSphs. Cell number was ana-
lyzed by Trypanblue exclusion after 7, 14 and 21 days. Note that treatment with MSC-CM decreases 
the absolute cell number around 80% in 50% MSC-CM and 100% MSC-CM compared to the control 
(A, B). After a small expansion phase 50% MSC-CM and 100% MSC-CM treated cells show a final 
plateau, whereas the control group shows an exponential growth curve (C).  
 
IV.2.3 MSC-CM enhances the expression pattern of glial and progenitor 
markers of proliferating mNSphs 
 
To determine whether MSC-CM affects the expression pattern of cell lineage specific 
markers, non-treated (control) and MSC-CM-treated proliferating mNSphs were dis-
sociated. After this procedure single cells were seeded overnight under serum-free 
conditions to allow them to attach. The cells were fixed and marker expression was 
analyzed in the following.  
Most of the cells carried from proliferating mNSphs expressed the glial progenitor 
markers A2B5 (approximately 25% figure 11 C, D) and NG2 (approximately 20% fig-
ure 11 E, F) and the stem cell marker Nestin (approximately 20% figure 11 A, B).  
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MSC-CM-treated proliferating mNSphs displayed a significant increase in the per-
centage of oligodendroglial progenitor markers NG2 and O4 (figure 11 E, F, G, H). 
However the percentage of A2B5 expressing cells was not chanced by treatment 
with MSC-CM. Further the MSC-CM-treated cells showed a significant increase of 
GFAP/Nestin expressing cells (figure 11 A, B from approximately 10% in the control 
group to approximately 40% in the 100% MSC-CM). At least, a few number of cells 
expressed the neuronal progenitor marker DCX by treatment with 100% MSC-CM 
(less than 2% figure 11 I, J). 
In summary these findings imply that soluble factors derived from MSCs in-
creased the percentage of glial and oligodendroglial markers of proliferating 
mNSphs. 
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Figure 11. Marker expression profile of proliferating mNSphs pre-incubated 21 days under con-
trol conditions, 50% MSC-CM and 100% MSC-CM. 
Treated mNSphs were dissociated and cells were seeded overnight under serum-free conditions and 
then fixed. Marker expression was analyzed by immunofluorescence. Illustrative fluorescence images 
are shown for Nestin (red), GFAP (green) and DAPI (blue) (A); A2B5 (red) and DAPI (blue) (C); NG2 
(green) and DAPI (blue) (E); O4 (red) and DAPI (G); and DCX (green) and DAPI (blue) (I). Quantita-
tive analysis for each marker are shown (B, D, F, H and J). Note the significant increase of 
GFAP+/Nestin+ cells (neural stem cell phenotype) in 100% MSC CM, compared with control condition. 
Also note that MSC-CM significant increase the percentage of cells expressing oligodendroglial pro-
genitor markers (NG2 and O4). * = p<0.05; ** = p<0.01; *** = p<0.001. Scale bar = 100µm 
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IV.2.4. MSC-CM enhances the expression of neural stem cell markers in 
proliferating mNSphs 
 
In a recent study it was shown that mNSphs under serum containing conditions dif-
ferentiate predominantly into astrocytes after GFW. In addition, a minor subpopula-
tion of mNSphs generated DCX-expressing neurons (Steffenhagen et al., 2011). 
It is one aim of this thesis to clarify if adult mNSphs differentiate into astro-
cytes after GFW, when they were treated in serum-free conditions before. Further-
more to check whether MSC-CM has also an oligodendrogenic response on mNSphs 
after GFW, non-treated and MSC-CM-treated proliferating mNSphs were dissociated 
and seeded overnight under serum-free conditions and incubated for 7 days without 
growth factors (FGF-2 and EGF).  
In contrast to the rNSphs, mNSphs showed a significant decrease in the per-
centage of the mature oligodendrogenic marker expression (MBP and CNPase) in 
the 50% MSC-CM and 100% MSC-CM treated group (figure 12 E, F, G, H). However 
MSC-CM displayed no influence on the O4 expression of mNSphs (figure 12 C, D).  
Admittedly we found a significant increase in expression of the astroglial/ neural stem 
cell markers GFAP/ Nestin in the 100% MSC-CM treated cell group, whereas the 
percentage of GFAP single labelled cells was decreasing (figure 12 A, B).  
Finally, there were few cells that express the neuronal progenitor markers DCX and 
MAP2ab in response to GFW (less than 4% figure 12 I, J, K, L) and MSC-CM treat-
ment did not affect its expression (figure 12 J, L).  
In summary, these data insinuated that MSC-CM has no effect on the oli-
godendrogenic ability of proliferating mNSphs on the one hand. But on the other 
hand MSC-CM may shift the cells towards an astrogenic / stem-cell fate like the in-
crease of the astroglial/ neural stem cell marker GFAP/ Nestin let us suggest. 
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Figure 12. Growth factor withdrawal response of mNSphs pre-incubated 21 days under control 
condition, 50% MSC-CM and 100% MSC-CM.  
Treated mNSphs were dissociated, seeded and incubated for one week under serum-free conditions 
without growth factors. After one week the cells were fixed and stained for immunohistochemistry. 
Marker expression was analyzed by immunofluorescence. Illustrative flourescence images are shown 
for: Nestin (red), GFAP (green) and DAPI (blue) (A); O4 (red) and DAPI (blue) (C); CNPase (red) and 
DAPI (blue) (E); MBP (red) and DAPI (G); DCX (green) and DAPI (blue) (I); and MAP2ab (red) and 
DAPI (blue) (K). Quantitative analysis for each marker are shown in the left panels (B, D, F, H, J and 
L). Note the significant increase in the percentage of cells that express neural stem cell markers 
(GFAP+/Nestin+) when mNSphs were grown in 100% MSC-CM respect to control condition. Note also 
that MSC-CM decreases the percentage of cells that express the mature oligodendrocyte marker 
MBP. * = p<0.05; ** = p<0.01; *** = p<0.001. Scale bar = 100µm 
 
 
 
 
 
IV.2.5 MSC-CM increases the rate of apoptosis of mNSphs and led the 
mNSphs to stem cells 
 
As we mentioned before the absolute number of proliferating mNSphs was decreas-
ing, when cells were incubated with 50% MSC-CM and 100% MSC-CM. To check, if 
these effect was caused through apoptosis or necrosis we performed a Cyto-
Tox96®Non-Radioactive Cytotoxicity Assay as described in III.2.10 7, 14 and 21 
days after seeding. 
We were able to show that 50% MSC-CM and 100%MSC-CM increase significant 
the LDH-activity, compared to the control (figure 13  A, B, C) both 7, 14 and 21 days 
after seeding, indicating that the anti-proliferative effect of MSC-CM on mNSphs is a 
toxic effect. Interestingly this cytotoxic effect was time-dependent. These data indi-
cated that MSC-CM induces apoptosis or necrosis in mNSphs.  
One possible mechanism for an improved cytotoxicity could be associated to 
changes of the cell cycle. We therefore investigated the effects of MSC-CM on the 
proliferation of mNSphs via FACS analysis 7 and 14 days after seeding as described 
in III.2.9. When the cells were incubated with 50% MSC-CM or 100% MSC-CM, 76% 
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respectively 52% of the cells were present in the G1/ S / G2M population, compared 
to 83% in the control group (figure 13 D, E, F). In contrast to these data cells, present 
in the G0 state increased from 17% in the control group to 24% respectively 48% in 
the 50% MSC-CM and 100%MSC-CM group. Similar to these data 14 days after 
seeding 85% of the control cells were in the G1/ S/ G2m state, whereas MSC-CM 
decreases these percentage to 73% in 50% MSC-CM respectively 6% in the 100% 
MSC-CM treated cells. In contrast to these data, the percentage of cells, which are 
present in the G0 state increased from 15% in the control group to 28% in the 50% 
MSC-CM treated group and 94% in the 100% MSC-CM treated group (figure 13 G, 
H, I). It seemed that treatment with MSC-CM led the cells in the G0-state of the cell-
cycle.  
 
 
 
 
Figure 13. Treatment with MSC-CM induces apoptosis/ necrosis in proliferating mNSphs and 
led the cells to the G0- state of the cell- cycle. 
mNSphs were cultured in normal proliferation medium (control), 50% MSC-CM and 100% MSC-CM for 
7, 14, and 21 days. After the accordant number of days a CytoTox96®Non-Radioactive cytotoxicity 
assay was performed first (A-C). Note the significant increase of LDH in the 50% MSC-CM and 100% 
MSC-CM treated group 7, 14 and 21 days after seeding.  
In a second step of experiments the effect of MSC-CM on proliferating mNSphs was performed via 
Fluorescence-Activated Cell Sorter (FACS analysis) 7 and 14 days after seeding (D-I). Note the in-
creased percentage of cells in the G0 state, when cells were treated with 50% and 100% MSC-CM. 
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IV.2.6 MSC-CM enhances the expression of the markers of self renewal  
 
After we saw the increase of cells in the G0 cell state, treated with 100% MSC-CM 
we aimed to analyse the expression pattern of markers which are known to show the 
self renewal potential of NSC. It’s known that Bmi1 is necessary for NSC self-renewal 
and it represses the cell cycle inhibitors p16, p19 and p21 (Fasano et al. 2009), as far 
as it’s known about the importance of Sox2 in the self renewal of NSC (Hu et al., 
2010).  
Therefore, proliferating mNSCs were incubated up to 3 weeks under normal 
proliferating conditions (control), 50% and 100% MSC-CM, the expression level of 
Bmi1 and Sox2 were analyzed by quantitative RT-PCR and the Bmi-1/ Sox2 ration 
was determined for the different conditions. The PCR revealed that the expression of 
Bmi1 and Sox2 was higher in the 50% MSC-CM and 100% MSC-CM treated group 
compared to the control, but not significant (figure 14 A, B, C). These data led us as-
sume that MSC-CM enhance the self renewal potential of proliferating NSC.  
 
 
 
 
 
Figure 14.Treatment with MSC-CM enhances the expression of markers of cell self renewal. 
Cells were treated with normal proliferation medium (control), 50% MSC-CM and 100% MSC-CM for 
21 days under normal proliferation conditions. The after 21 days performed PCR showed an increase 
in the percentage of the markers Bmi-1, Sox2 and FoxO3, which led us suggest that treatment with 
MSC-CM enhance the self-renewal potential of mNSphs (A-C). 
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V. Discussion 
 
This thesis aimed to characterise the different effects of MSC-CM on adult proliferat-
ing rat and mouse neural hippocampal stem cells.  
 
The studies and results of this thesis demonstrated that soluble factors derived from 
MSCs activated an oligodendrogenic program (OPr) and promoted the pre-
disposition of proliferating adult rNSPCs towards an oligodendrocyte fate. In contrast 
to these investigations proliferating adult mNSPCs displayed no pre-disposition to-
wards an oligodendrocyte fate, but MSC-CM shifted them towards an astroglial line-
age and may have increased the mNSPCs stemness.  
 
V.1 MSC-CM primes the oligodendrogenic program in proliferating 
adult rNSCs 
 
Over the last years several research groups studied the influence of different stimuli 
on proliferating and differentiating adult NSCs. Adult hippocampal NSCs, as used in 
this thesis showed the main characteristics of NSCs – named the ability of self-
renewal and the generation of both glia and neurons in vitro and in vivo (Palmer et 
al., 1997; Boda and Buffo, 2010).  
At first these NSCs can be encouraged to proliferate, which means to maintain the 
stem cell character. They can further be provided to differentiate into mature neural 
cell types via several steps by withdrawing mitogenic growth factors and / or adding 
specific factors promoting differentiation into particular neural lineages. A neuronal 
differentiation can be reached through retinoic acid (RA), Platelet derived growth fac-
tor – AA (PDGF – AA), PDGF – AB, PDGF - BB and neurotrophin-3 (NT- 3) (Johe et 
al., 1996). Ciliary neurotrophic factor (CNTF), Leukemia inhibitory factor (LIF) and 
bone morphogenetic protein-2 and -4 (BMP-2/-4) induce astrocytic differentiation 
(Mayer et al., 1994; Johe et al., 1996; Cheng et al., 2007) while insulin-like growth 
factor-1 (IGF-1) and mesenchymal stem cell conditioned media (MSC-CM) induce 
oligodendroglial differentiation (Hsieh et al., 2004; Rivera et al., 2006). The thyroid 
hormone T-3 influences the differentiation of multipotent precursors of the adult rat 
brain toward a mixed glial fate (Johe et al., 1996). It is apparent from previous studies 
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that four distinctly different subsets of ligand-receptor superfamilies are involved in 
determining the fate of adult NSCs. These include 1) the transforming growth factor 
type-beta-1 (TGF-beta1) and bone morphogenetic protein (BMP) superfamily; 2) the 
platelet-derived and epidermal (PDGF/EGF) growth factors; 3) the interleukin-6, leu-
kemia inhibitory factor, and ciliary neurotrophic factor (IL-6/LIF/CNTF) superfamily; 
and 4) the EGF-like Notch/Delta group of extracellular ligands (Mondal et al., 2004). 
Although lineage specifications can be reached through GFW, it seems that 
cell priming as a well as cell fate and lineage decisions are taken while progenitors 
are still proliferating (Rivera et al., 2010). For example, PDGFα in cooperation with 
bFGF converts embryonic derived proliferating neurospheres into oligospheres, 
which consist of oligodendrocyte precursor cells (Pedraza et al. 2008). Transient ex-
posure to lithium chloride during in vitro proliferation has the ability to alter the differ-
ential fate of rNSCs in vitro and increase the proportion of cells expressing neuronal 
markers while at the same time causing a reduction in glial progeny (Vazey and 
Connor, 2009). A mixture of FGF, heparin and laminin was further shown to prime 
adult human neuronal progenitors towards neurons (Olstorn et al., 2011). For instead 
the data of this thesis demonstrated that MSCs prime proliferating NSCs, reinforcing 
cell fate decision and accelerating differentiation towards oligodendrocytes.  
However other data indicate that cell fate decision might also occur after cell-
cycle exit, when cells are differentiating. Indeed, it was shown that it is not sufficient 
to force spinal cord derived neural progenitor cells to the cell-cycle to alter the cell 
fate decision of these cells (Lobjois et al., 2008). Therefore, cell fate decisions and 
cell progenitor priming might represent different independent biological events. While 
the first could occur independently of cell cycle exit and involved the cell lineage de-
termination, the second might particularly take place in proliferating progenitors and 
consist on a pre-disposition induction towards a certain cell lineage that boost the 
fate choice and ends up on a faster differentiation. 
In the present work, it was described that soluble factors derived from MSCs 
promote the pre-disposition of proliferating adult rNSCs towards an oligodendrocyte 
fate. MSC – CM did not impinge on cell proliferation, nor did it modify the expression 
pattern of typical neural / oligodendroglial progenitor markers. However, it pre-
disposed and / or accelerated progenitors to differentiate into mature MBP express-
ing oligodendrocytes and generated a higher amount of CNPase positive cells.  
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A surprising observation within the present work is the notion that the majority 
of progenitors (approximately 60%) that were generated under control conditions dif-
ferentiated into MBP expressing oligodendrocytes in serum-free conditions. For in-
stance, after GFW rNSCs differentiated into MBP-expressing adult oligodendrocytes, 
which was enhanced by MSC-CM (Steffenhagen, et al., 2011). This suggests that the 
progenitors used in the present study where already partly committed to an oligoden-
droglial fate. This tendency to generate oligodendrocytes might not have been 
minded in many previous studies, since most of the differentiation assays are typi-
cally performed in serum-containing, and thus astrocyte-inducing, media.  
 
Little is known about the molecular mechanism how MSC-CM induces an oli-
godendroglial activity. During the NSCs differentiation, cells change their internal 
program from the self-renewal state to a committed fate. When differentiation is acti-
vated, specific cell fate genes are up-regulated by activator markers, while repressor 
markers are lost (Azuara et al., 2006 ; Spivakov  et al., 2007; Gaspar-Maia et al., 
2009; Bernstein et al., 2006). It seems that the effect of MSC-CM involves the regula-
tion of Olig and Id proteins. Olig1 and Olig2 play an important role in oligodendroglial 
fate determination of neural progenitors during the development of the CNS as well 
as during oligodendrogenesis in the adulthood (Ross et al., 2003). Their inhibition 
leads to the abolishment of oligodendrocyte differentiation (Zhou and Anderson, 
2002). The inhibitor of differentiation 2 (Id2) and 4 (Id4) proteins interact with Olig1 
and Olig2 by sequestration of the Olig factors and their binding partners E12 and E47 
so that the Olig-E complex cannot be formed and its entry into the nucleus is pre-
vented (Wang et al., 2001). Therefore, oligodendroglial fate determination of neural 
progenitor cells is inhibited and astrocytic differentiation encouraged. That is why the 
ratio of the amount of Olig and Id2 proteins is a key determinant for oligodendrocyte 
versus astrocyte fate decision (Samanta and Kessler, 2004). In a previous study, it 
was already demonstrated that MSC-CM induces Olig2 and reduces Id2 expression 
in neural progenitors that underwent serum-induced differentiation (Rivera et al., 
2006). Under proliferation conditions, MSC-CM did not increase Olig2 expression, 
but constrained the expression of Id2 and thus raised the Olig2/Id2 ratio. As a conse-
quence, the Id2 appears to be a key regulator in the process. Since Id2 is up-
regulated by BMPs signalling (Samanta and Kessler, 2004), MSC-CM might block 
BMPs signalling in order to decrease Id2 expression. Along this line, the BMPs an-
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tagonist noggin induces oligodendrogenesis of human embryonic progenitors (Izrael 
et al., 2007) suggesting noggin as a candidate factor present in the MSC-CM. How-
ever, in our previous work we excluded noggin as the oligodendrogenic activity pre-
sent in MSC-CM (Rivera et al., 2008). Nevertheless, the possibility that MSC-CM ac-
tivate a signal transduction pathway that decreases Ids expression suggests a link or 
crosstalk to BMP signalling. 
 
In conclusion, MSCs exert a potent oligodendrogenic effect on adult rat NSCs pro-
moting and enhancing cell fate decision, differentiation and maturation. Both, the 
identification of the MSCs derived oligodendrogenic activity as well as the clarification 
of the molecular mechanism underlie are crucial to develop new therapies for the 
treatment of demyelinating diseases. Demyelinating diseases, such as multiple scle-
rosis (MS) or spinal chord injury, are characterized by the loss of oligodendrocytes 
resulting in several neurological symptoms including paralysis. Enhancing oligoden-
drogenesis and promoting remyelination might be an attractive approach to counter-
act this situation. The feasibility of this approach is provided by the fact that oli-
godendrogenesis occurs during adulthood, where neural and oligodendroglial pro-
genitors are the cellular source of remyelinating cells. 
 
 
V.2 MSC-CM enhances the expression of astrocyte / stem cells 
markers on proliferating adult mNSCs 
 
In a second trial of experiments the effects of soluble factors derived from MSCs on 
proliferating mNSCs have been explored. In previous studies it was shown that adult 
mNSCs strongly express Nestin, used as stem cell marker, and GFAP, used as 
marker for astrocytes (Steffenhagen et al., 2011).  
Coincident with these observations an astroglial/ stem cell marker expression 
of proliferating mNSCs was detected, which gave rise mainly to astrocytes as well as 
to some neurons after GFW. After the treatment with MSC-CM the expression of 
GFAP/Nestin was significantly enhanced in proliferating mNSCs. On the base of 
these observations it was hypothesized that MSC-CM could proliferating mNSCs shift 
towards an astroglial/ stem cell identity.  
  
 
V. DISCUSSION - 55 -
 
On this point someone could argue, based on the increase on the proportion of 
Nestin- and GFAP-expressing cells, that mNSCs are more stem cell-like than rNSCs 
and MSC-CM may enhance the stemness of proliferating mNSCs. But actually, there 
are no markers that are specific for adult NSCs. Nestin and GFAP are markers for 
precursors and astrocytes. However radial glia cells and astrocytes are considered to 
be the NSCs in the SGZ of the dentate gyrus, called type-1 cells (Seri et al., 2001). 
Type-1 cells express the astrocyte marker GFAP as well as Nestin and Sox2. They 
give rise to type-2 cells, which are highly proliferative progenitor cells and can be dif-
ferentiated into two subtypes: DCX-negative type-2a cells and DCX-expressing type-
2b cells. Type-2a cells generate type-3 cells, which represent the migrating neuro-
blasts and differentiate into mature neurons (Kempermann et al., 2004).  
Although mNSCs display a stem cell identity by the expression of GFAP / Nestin they 
are no true stem cells, because they don’t show the main characteristics of stem 
cells. Multipotency and the potential of self-renewal are these main characteristics of 
stem cells. In a previous study Steffenhagen showed that mNSCs display a restricted 
differentiation potential (Steffenhagen et al., 2011). After GFW as well as after addi-
tional treatment with neurogenic, astrogenic and oligodendrogenic stimuli, namely 
RA, BMPs and MSC-CM, mNSCs gave rise to astrocytes and some neurons but they 
could not generate oligodendrocytes (Steffenhagen et al., 2011). So it was concluded 
that mNSCs display an intrinsic astrogenic fate potential and were shifted back to an 
astroglial / stem cell fate by MSC-CM. To verify the true stem cell character of these 
MSC-CM treated cells more experimental approach is necessary to demonstrate the 
multipotency as well as the self-renewal capacity of these cells. 
 
Although the cellular mechanisms that underlie the MSC-CM impact of proliferating 
mNSCs remain unclear, it might imply cell proliferation and cell death. Thus, together 
with a reduction in the proliferation rate of mNSCs after treatment with MSC-CM, an 
elevated rate of cell death was observed.  
First, the anti-proliferative MSC-CM activity on mNSCs might involve the cell cycle. 
As described before the residual mNSCs after the treatment with MSC-CM displayed 
a significant reduction in cell proliferation as well as elevated levels of the astroglial / 
stem cell markers GFAP/Nestin. There it was hypothesized that MSC-CM increases 
the stemness of proliferating adult mNSCs by cell cycle modification.  
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The cell cycle consists of four distinct phases: G1 phase, S phase (synthesis), G2 
phase (collectively known as interphase) and M phase (mitosis). In the G0 state, the 
cell has left the cycle and has stopped dividing (cell cycle arrest). These cells are 
stem cells or differentiated cells normally. The experiment of this thesis demonstrated 
that MSC-CM leads mNSCs towards a cell cycle arrest, so that the mNSCs were 
more quiescent. This means that MSC-CM promotes either stem cells or led the adult 
mNSCs differentiate into astrocytes. Although stem cells exhibit a slower proliferation 
rate than progenitors, as this thesis sowed and although the remaining cells exhibit 
the astroglial / stem cell markers GFAP/Nestin it remains unclear if these cells are 
true stem cells or if they just display few stem cell features.  
Second, a MSC-CM cytotoxic effect on proliferating mNSCs was also found by in-
creased LDH levels. LDH is an intracellular enzyme present in a wide variety of or-
ganisms, including plants and animals. Given that the LDH is an intracellular enzyme, 
a higher amount of the measurable extracellular LDH is an indicator for cell death. 
Cell death can occur through apoptosis and necrosis. Apoptosis is the process of 
programmed cell death. Biochemical events lead to characteristic cell changes (mor-
phology) and death. These changes include blebbing, loss of cell membrane asym-
metry and attachment, cell shrinkage, nuclear fragmentation, chromatin condensa-
tion, and chromosomal DNA fragmentation. Apoptosis differs from necrosis, which is 
a form of traumatic cell death that results from acute cellular injury. After necrosis the 
cellular debris can damage other cells of the organism. The process of apoptosis is 
controlled by a diverse range of cell signals, which may originate either extracellularly 
(extrinsic inducers) or intracellularly (intrinsic inducers). Extracellular signals may in-
clude toxins, hormones, growth factors, nitric oxide or cytokines (Popov et al., 2002; 
Brüne, 2003). Although a cytotoxic impact of MSC-CM on proliferating mNSCs 
through elevated LDH-levels was attested, it is not possible to distinguish if MSC-CM 
dispatch mNSCs randomly or selectively nor it can be distinguished if MSC-CM acti-
vates the process of the programmed cell death (apoptosis). It remains also unclear if 
MSC-CM has an inductive effect on a minor astrocyte/stem cell subpopulation of pro-
liferating mNSCs. It would have to be demonstrated if MSC-CM has a selective or an 
inductive impact on proliferating mNSCs through pulse-chase experiments to deter-
mine the propidium iodide (PI) incorporation and staining of the different cell sub-
populations. PI is an intercalating agent and a fluorescent molecule that can be used 
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to stain DNA (Sakimoto et al., 2006). It can be used to differentiate necrotic, apoptotic 
and normal cells (Lecoeur 2002). 
 
To demonstrate the real stem cell character of these remaining cells after treatment 
with MSC-CM, the two main stem cell criteria must be verified: multipotency and self-
renewal. Multipotency can be evidenced if these cells can differentiate into neurons, 
astrocytes and oligodendrocytes after the treatment with neurogenic, astrogenic and 
oligodendrogenic stimuli. If the remaining cells are still able to self-renew, it can be 
demonstrated through a secondary neurosphere assay. For that, cells from the pri-
mary NSph culture are dissociated and single cells are plated to explore whether 
these single cells are able to form secondary NSph.  
 
The molecular mechanism of the MSC-CM induced astroglial/ stem-cell activity isn’t 
identified yet. Multiple cell-intrinsic regulators coordinate with the microenvironment 
through various signalling pathways the regulation of adult mNSCs cell maintenance, 
self-renewal, and fate determination. These regulators include the nuclear hormone 
receptor TLX (tailless), the high-mobility-group transcription factor Sox2 (sex deter-
mining region of Y chromosome-related high mobility group box 2), the basic helix-
loop-helix (bHLH) transcriptional repressor Hes (hairy and enhancer of split), the tu-
mour suppressor phosphatase Pten (phosphatase and tensin homolog deleted on 
chromosome 10), and the Drosophila membrane-associated protein Numb ho-
mologs, Numb and Numblike (Qu and Shi, 2009). The Sox2 transcription factor is 
also expressed at high levels in neural stem and progenitor cells in both embryonic 
and adult brains (Episkopou, 2005). Along with Sox1 and Sox3, two other members 
of the Sox family, Sox2 has been shown to maintain neural stem cell identity in the 
developing brain. Constitutive expression of Sox2 inhibited neuronal differentiation 
and maintained neural progenitor characteristics, whereas inhibition of Sox2 led to 
precocious neuronal differentiation (Bylund et al., 2003; Graham et al., 2003). The 
polycomb family transcriptional repressor Bmi-1 is required for the self-renewal and 
post-natal maintenance neural stem cells from the CNS and PNS (Molofsky et al. 
2003). Through further experiments we showed that MSC-CM involves the regulation 
of Bmi and Sox proteins in proliferating mNSCs. Through the elevated levels of these 
transcription factors we hypothesized that MSC-CM promotes self-renewal in prolif-
erating mNSCs. Although Sox-2 and Bmi-1 are possible marker for self renewal, a 
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main characteristic of stem cells, the elevated levels of markers are not enough to 
identify stem cells.  
 
In summary, it looks like that MSC-CM could induce an astrogenic / stem-cell fate on 
proliferating adult mNSCs. However the molecular pathways to reach this astrogenic/ 
stem-cell fate decision are not clear in detail, it seems that Bmi-1 and Sox2 play an 
important role. It is moreover unclear if MSC-CM has a de-differentiative process or a 
selective effect just as MSC-CM looks to be cytotoxic to mNSCs. To clarify this issue 
if the effect of MSC-CM is a de-differentiation process or a selection, more experi-
mental approach is necessary. However the stem-cell potential of these residual cells 
must be evaluated to confirm the multipotency and the possibility of self-renewal of 
these cells.  
 
V.3 In vivo clinical relevance of MSCs and NPCs interaction 
 
Although a lot of key facts are poorly understood yet, such reports have fuelled ex-
pectations for the clinical exploitation of neural stem cells in cell replacement or re-
cruitment strategies for the treatment of a variety of human neurological conditions 
including Parkinson's disease, Huntington's disease, multiple sclerosis and ischemic 
brain injury. Especially our finding that MSCs prime proliferating rNSC towards an 
oligodendroglial fate is of huge relevance in the treatment of demyelinating diseases 
since proliferating progenitors commonly surround CNS lesions in high numbers, but 
the processes of migration, differentiation and maturation in myelinating cells are de-
fective in the case of these demyelinating diseases (Williams et al., 2007). It looks 
like that this lack of myelin-promoting activities might contribute to the impairment of 
remyelinisation in MS, as an example for demyelinating diseases. Searching the rea-
son for this lack of myelin-promoting activities in MS, aging was detected as a possi-
ble risk factor, since endogenous remyelination is drastically affected in aged sub-
jects. This age related decrease in remyelination is due to a deficient OPCs recruit-
ment and differentiation (Sim et al., 2002). Thus, while remyelination impairment in 
MS and in particular during aging is partly derived from the failure to differentiate into 
oligodendrocytes, a lack of sufficient oligodendroglial commitment in proliferating 
progenitors might contribute to this deficiency. Therefore, the fact that MSCs not only 
induce an oligodendrocyte differentiation (Rivera et al., 2006) but also prime prolifer-
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ating NPCs towards an oligodendrocyte fate might have in vivo and clinical relevance 
when aiming to develop remyelinating therapies for MS in young as well as in old pa-
tients. 
Moreover neural stem cells may also find potential clinical application as cellular vec-
tors for widespread gene delivery and the expression of therapeutic proteins through 
their ability of migration (Ostenfeld and Svendsen, 2003).  
Since large numbers of stem cells can be generated efficiently in culture, 
they may obviate some of the technical and ethical limitations associated with the 
use of fresh (primary) embryonic neural tissue in current transplantation strategies. 
It’s of huge relevance to get multipotent stem cells from non embryonic stem cells. 
Our findings that MSCs increase the stemness in proliferating mNSCs show the pos-
sibility to induce a stem cell fate from proliferating progenitors. 
While considerable recent progress has been made in terms of developing 
new techniques allowing for the long-term culture of adult NSCs, the successful clini-
cal application of these cells is presently limited by the understanding of both (1) the 
intrinsic and extrinsic regulators of stem cell proliferation and (2) those factors con-
trolling cell lineage determination and differentiation. Although such adult NSCs may 
also provide accessible model systems for studying neural development, progress in 
the field has been further limited by the lack of suitable markers needed for the identi-
fication and selection of precursor and stem cells. There is a further need to distin-
guish between the committed fate (defined during normal development) and the po-
tential specification (implying flexibility of fate through manipulation of its environ-
ment) of stem cells undergoing differentiation. With these challenges lying ahead 
stem-cell therapies are likely to remain within the experimental arena for the foresee-
able future. 
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Abstract  
 
Oligodendrogenesis encompasses lineage specification of neural progenitors (NPCs) 
and differentiation into oligodendrocytes, which ultimately culminates in the myelination of 
central nervous system axons. Each individual process must be tightly regulated by extracel-
lular and cell-intrinsic mechanisms, whose identities are barely known. We had previously 
demonstrated that soluble factors derived from rat mesenchymal stem cells (MSCs) induce 
oligodendrogenesis in differentiating adult NPCs under differentiation conditions. However, 
since lineage specification predominantly occurs in proliferating progenitors and not necessar-
ily during early differentiation, we investigated if soluble factors derived from MSCs are able 
to prime NPCs to the oligodendroglial fate already under proliferation conditions. Therefore, 
we analyzed the effects of a three weeks stimulation of adult NPCs under proliferation condi-
tions with conditioned media derived from MSCs (MSC-CM) in terms of cell morphology, 
proliferation, cell-specific marker expression profile, response to growth factor withdrawal, 
cell-lineage restriction, and expression of glial fate determinants. While MSC-CM did not 
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affect the proliferation rate of NPCs, it boosted the formation of CNPase- as well as MBP-
expressing oligodendrocytes after growth factor withdrawal, even when cells were exposed to 
an astrogenic milieu. Moreover, it reinforced the proper development of oligodendrocytes, 
since it ensured a sustained expression of the functional marker CNPase. Finally, in proliferat-
ing NPCs, the presence of MSC-CM reduced the anti-oligodendrogenic determinant Id2, thus 
increasing the relative proportion of the pro-oligodendrogenic factor Olig2 expression. In 
summary, MSCs prime proliferating progenitors and, thus, reinforce cell fate choice and ac-
celerate differentiation towards the oligodendrocyte lineage. The present findings underscore 
the potential use of MSCs in cell therapies for remyelination such as in multiple sclerosis and 
spinal cord injury. Moreover, they urge the identification of the oligodendrogenic activity(ies) 
derived from MSCs in order to develop novel molecular therapies for demyelinating diseases.  
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Introduction 
 
Oligodendrocytes are one of the three main neuroectodermal cell types within the cen-
tral nervous system (CNS). Their main function is to form myelin that wraps axons to facili-
tate saltatory electric conductance [1]. Demyelinating diseases, such as multiple sclerosis 
(MS), are characterized by the loss of oligodendrocytes resulting in severe neurological symp-
toms such as hemiparesis or visual impairment. Enhancing oligodendrogenesis and promoting 
remyelination might be an attractive approach to counteract this situation. The feasibility of 
this approach is provided by the fact that oligodendrogenesis can occur during adulthood. 
Oligodendrocyte progenitors cells (OPCs) are widespread throughout the CNS in white and 
grey matter, representing 5 to 8% of total glial cells [2,3] and constitute the major cellular 
source of remyelinating cells [4]. Upon demyelination, endogenous OPCs start to proliferate 
and the expression of oligodendrogenic genes is induced. After OPCs activation, cells are 
recruited towards the lesion site where they differentiate and maturate into myelinating oli-
godendrocytes [4,5]. However, OPCs are not unique in the ability to remyelinate, since sub-
ventricular zone (SVZ) derived neural stem cells (NSCs), beside their neurogenic potential, 
represent a source for new oligodendrocytes [6-9]. Under normal physiological conditions as 
well as in response to demyelinating insults, SVZ derived NSCs migrate into the corpus callo-
sum, the striatum and to the fimbria fornix where they give rise to myelinating oligodendro-
cytes [6-8,10]. In addition to this, cells residing in the subcallosum zone (SCZ) also enter the 
corpus collosum and generate oligodendrocytes [11]. Therefore, the adult CNS is equipped 
with different cellular sources for remyelination and regenerative mechanisms in response to 
demyelination.  
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Oligodendrogenesis is a hierarchically structured process that involves i) specification 
of proliferating neural stem / progenitor cells to the oligodendroglial lineage via glial and sub-
sequently oligodendroglial progenitors, ii) migration of progenitors and differentiation into 
oligodendrocytes, and iii) myelination of axons [12-14] (Fig. 1A). This process involves the 
sequential generation of several cell types that display distinct proliferation and differentiation 
properties. Due to the cell-specific marker expression profile, each cell type can be monitored 
and identified in vivo and in vitro (Fig. 1A). Each individual step in oligodendrogenesis is 
tightly regulated by extracellular and cell-intrinsic mechanisms. For example, platelet derived 
growth factor (PDGF) and sonic hedgehog (Shh) are potent activators of oligodendrogenesis 
[15-18], while bone morphogenetic proteins (BMPs) inhibit the generation of oligodendro-
cytes. BMPs induce the expression of the inhibitors of differentiation 2 and 4 (Id2 and Id4), 
which sequester the pro-oligodendrogenic transcription factors Olig1 and Olig2 in the cyto-
plasm avoiding their entrance into the nucleus [19]. Therefore, Olig1/2 and Id2/4 proteins are 
glial fate determinants and the balance between their expression level plays a crucial role for 
the astrocyte / oligodendrocyte decision.   
 
Recently, we and others had shown that conditioned medium derived from mesen-
chymal stem cells (MSCs) promote expression of myelin basic protein (MBP) and oligoden-
drogenesis in differentiating NPCs [20-22]. Moreover, we demonstrated that MSCs promote 
oligodendroglial differentiation of NPCs that were co-transplanted into a hippocampal slice 
[23]. Thus, factors derived from MSCs strongly promote oligodendrogenesis of differentiating 
cells. It is, however, unclear, if MSC-CM targets progenitors and specifies them towards the 
oligodendroglial fate also under proliferation conditions. Obviously, this is of huge relevance, 
since proliferating progenitors commonly surround CNS lesions in high numbers, but often 
fail to remyelinate sparse axons [24,25]. Moreover, this situation becomes more evident and 
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relevant in aged subjects [26-28]. While the deficiency to remyelinate is partly derived from 
the failure to differentiate into oligodendroglia [24,26-28], a lack of sufficient oligodendro-
glial commitment in proliferating progenitors might contribute to this deficiency. Here, we 
test the hypothesis that MSC derived soluble factors are able to predispose or prime proliferat-
ing NPCs towards an oligodendroglial fate.  
Materials and Methods 
 
Animal subjects 
Adult female Fischer 344 rats (Charles River Deutschland GmbH, Germany) were 
used as donors for the NPCs and MSCs cultures. All experiments were carried out in accor-
dance with the European Communities Council Directive (86/609/EEC) and institutional 
guidelines. Animals had ad libitum access to food and water throughout the study.  
 
Rat NPCs cultures and neurospheres formation  
 
 
NPCs derived from the adult hippocampus were generated as described [20,29]. 
Briefly, 2 to 4 month-old rats (Charles River Deutschland GmbH, Germany) were decapi-
tated. Hippocampi were aseptically removed, transferred to 4°C DPBS (PAN, Germany) with 
4.5g/L glucose (Merck, Germany) (DPBS/glu), washed once, transferred to petri dishes and 
dissociated mechanically. The cell suspension was washed in DPBS/glu and resuspended in 
PPD-solution containing 0.01% Papain (Worthington Biochemicals, England), 0.1% dispase 
II (Boehringer, Germany), 0.01% DNase I (Worthington Biochemicals, England) and 12.4 
mM MgSO4 in HBSS (PAN, Germany) without Mg++/Ca++ (PAA, Germany) and digested for 
30 to 40 min at 37°C. The cell suspension was triturated every 10 min. Dissociated cells were 
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collected and resuspended in Neurobasal (NB) medium containing B27 (Gibco BRL, Ger-
many), 2mM L-glutamine and 100U/mL penicillin/ 100 µg/ml streptomycin and washed three 
times. Finally, the single cell suspension was resuspended in NB medium (Gibco BRL, Ger-
many) supplemented with B27 (Gibco BRL, Germany) (NB/B27), 2 mM L-glutamine (PAN, 
Germany), 100U/mL penicillin/ 100 µg/ml streptomycin (PAN, Germany), 2 µg/ml heparin 
(Sigma, Germany), human recombinant 20 ng/ml FGF-2 (R&D Systems GmbH, Germany) 
and human recombinant 20 ng/ml EGF (R&D Systems GmbH, Germany). Cultures were 
maintained at 37°C in an incubator with 5% CO2. Half of the medium was changed every 3 to 
4 days. After 1 to 2 weeks NPCs formed neurospheres and were passaged. Thereafter, neuro-
spheres were passaged once a week and were grown for 2 to 3 weeks to reach passage 2. Neu-
rospheres cultures from passage number 2 to 6 were used throughout this study. 
 
Rat MSCs cultures and conditioned medium preparation (MSC-CM) 
 
MSCs were prepared as described previously [20]. Briefly, bone marrow plugs were 
harvested from femurs and tibias of 2-4 month-old female Fisher-344 rats (Charles River 
Deutschland GmbH, Germany). Plugs were mechanically dissociated in αMEM (Gibco Invi-
trogen, Germany) and recovered by centrifugation. Cell pellets were resuspended in αMEM-
10% FBS and seeded at 1x106 cells/cm2. After 3 days, media was changed and non-adherent 
cells were removed. Adherent cells were incubated in fresh αMEM-10% FBS until a conflu-
ent layer of cells was achieved. Cells were trypsinized using 0.25% Trypsin (Gibco Invitro-
gen, Germany) and seeded in αMEM-10% FBS at 8,000 cells/cm2. After 3-5 days of culture, 
the resulting monolayer of cells, hereafter named rat bone marrow-derived mesenchymal stem 
cells (MSCs), was trypsinized and further cultured for experiments or frozen for later use. As 
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demonstrated in our previous work, this cell culture preparation is highly enriched in multipo-
tent MSCs with virtually no hematopoietic contamination [20].  
 
Mesenchymal stem cell conditioned medium (MSC-CM) was prepared similar as de-
scribed [20] with the exception of the media used. MSCs were plated at 12,000 cells/cm2 and 
incubated in normal NPCs proliferation medium (NB medium supplemented with B27 
(NB/B27), 2 mM L-glutamine, 100U/mL penicillin/ 100 µg/ml streptomycin, 2 µg/ml hepa-
rin, human recombinant 20 ng/ml FGF-2 and human recombinant EGF 20 ng/ml). After 3 
days, the conditioned medium was collected and filtered using a 0.22 µm-pore filter. In some 
of the experiments, the conditioned medium was replenished with EGF and FGF-2 (20 ng/ml 
each) to exclude the possibility that MSCs might have consumed the growth factors.  
 
 
NPCs stimulation with MSC-CM and cell number analysis  
 
5x104 NPCs/ml were incubated up to 3 weeks either in normal NPCs proliferating 
medium (control) or in complete MSC-CM (MSC-CM). Alternatively, cells were incubated in 
a half/half mixture between normal NPCs proliferation media and MSC-CM (50% MSC-CM) 
or in MSC-CM comprising 20 ng/ml FGF-2 and 20 ng/ml EGF (MSC-CM + GF).  Media was 
changed after 3 to 4 days.  
 
Neurospheres proliferation was explored by determining the cell number for control 
condition, 50% MSC-CM, 100% MSC-CM and MSC-CM + GF through Trypan blue (Sigma-
Aldrich, Germany) exclusion and MTS assay (CellTiter 96 Aqueous One Solution Cell Pro-
liferation Assay, Promega, Germany) as well as by measuring the number of neurospheres 
and the mean neurosphere diameter.   
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For Trypan blue exclusion 5x104 cells/ml were seeded in the above mentioned media. 
After 7, 14 and 21 days, cell number was determined by Trypan blue exclusion. The neuro-
spheres and the cells that were adherent after MSC-CM treatment were detached and dissoci-
ated with Accutase and treated with Trypan blue. Following, the number of living cells was 
determined using a light microscope (Zeiss, Germany).  
 
For the MTS assay, untreated cells and cells that were treated for one week with 50% 
MSC-CM, 100% MSC-CM or MSC-CM + GF were seeded in the respective media into 96-
well plates at a density of 2x104 cells/cm2. The assay was performed according to the manu-
facturer’s instructions. On day 0, 2, 4 and 7 the optical density was measured at 490nm in a 
microplate reader (Berthold Technologies, Austria) after 3 hours of incubation with the MTS 
solution.  
 
Similar to the MTS assay cells in normal proliferation media and cells that were 
treated for one week with 50% MSC-CM, 100% MSC-CM or MSC-CM + GF were used to 
determine the neurospheres number and diameter.  Cells were seeded at a density of 1,5x104 
cells/cm2 and incubated in the respective media for 2, 4 or 7 days. The number of neuro-
spheres was analyzed by Trypan blue exclusion under a light microscope. The neurospheres 
diameter was determined using Olympus IX81 inverted microscope equipped with 
Hamamatsu digital camera and Volocity 5.4.1 software (PerkinElmer, Germany). 
 
Expression profile analysis of cell-lineage-specific markers 
  
NPCs were incubated under normal proliferating medium (control), 50% MSC-CM, 
100% MSC-CM, and MSC-CM replenished with growth factors (MSC-CM + GF). After 3 
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weeks, marker expression profile was determined.  For some experiments, RNA was isolated 
directly from the neurospheres after the 3 weeks treatment period and processed for qRT-
PCR. Alternatively, the floating neurospheres as well as the cells that got adherent under the 
MSC-CM treatment were dissociated with Accutase (Innovative Cell Technologies Inc., dis-
tributed by PAA) and then plated on 100 µg/ml poly-L-ornithine (Sigma-Aldrich, Germany) 
and 5 µg/ml laminin-coated (Sigma-Aldrich, Germany) glass coverslips (2.5x104 cells/cm2) 
for subsequent immunofluorescence stainings or seeded in 100 µg/ml poly-L-ornithine and 5 
µg/ml laminin-coated plates (2x104 cells/cm2) for subsequent RNA isolation. The dissociated 
cells were incubated in DMEM Knockout-20% Serum Replacement supplement (SR) (Gibco 
Invitrogen, Germany) for 12 hours. This serum-free media has been used for embryonic stem 
cell maintenance and does not induce differentiation [30-32]. Under these conditions dissoci-
ated NPCs attach to the plate in the absence of serum. To analyze the expression of cell-
lineage-specific markers, cells were either fixed for 30 minutes with 4% paraformaldehyde 
and processed for immunofluorescence or RNA was isolated from the cells and used for qRT-
PCR.  
 
Growth factor withdrawal response  
 
NPCs were incubated under normal proliferation medium (control), 50% MSC-CM, 
100% MSC-CM, and MSC-CM replenished with growth factors (MSC-CM + GF). After 3 
weeks, the response to growth factor withdrawal was determined. First, floating neurospheres 
as well as the cells that were adherent after MSC-CM treatment were detached and dissoci-
ated with Accutase (Innovative Cell Technologies Inc., distributed by PAA). Then, the disso-
ciated cells were plated on 100 µg/ml poly-L-ornithine (Sigma-Aldrich, Germany) and 5 
µg/ml laminin-coated (Sigma-Aldrich, Germany) glass coverslips (2.5x104 cells/cm2) for sub-
sequent immunofluorescence stainings or directly in 100 µg/ml poly-L-ornithine and 5 µg/ml 
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laminin-coated plates (2.5x104 cells/cm2) for subsequent RNA isolation. The cells were incu-
bated in DMEM Knockout-20% Serum Replacement supplement (SR) (Gibco Invitrogen, 
Germany) for 3 or 7 days. Cells were then fixed for 30 minutes with 4% paraformaldehyde 
and processed for immunofluorescence or, alternatively, RNA was isolated from the cells and 
used for qRT-PCR.  
 
Astrogenic potential and cell-lineage restriction analysis 
  
NPCs were incubated with normal proliferation medium (control), 50% MSC-CM and 
100% MSC-CM. After 3 weeks, the astrogenic potential was determined. Floating neuro-
spheres  as well as the cells that were adherent after MSC-CM treatment were detached and 
dissociated with Accutase (Innovative Cell Technologies Inc., distributed by PAA) and plated 
on 100 µg/ml poly-L-ornithine (Sigma-Aldrich, Germany) and 5 µg/ml laminin-coated 
(Sigma-Aldrich, Germany) glass coverslips at a density of 2.5x104 cells/cm2 in αMEM 
(Gibco Invitrogen, Germany) and 10% FBS (Lonza, Germany) was added as an astrogenic 
stimulus. After 7 days, cells were fixed for 30 minutes with 4% paraformaldehyde and proc-
essed for immunofluorescence to detect the expression of the different cell-lineage-specific 
markers. 
  
Immunofluorescence  
 
Fixed cells were washed in TBS (0.15 M NaCl, 0.1 M Tris-HCl, pH 7.5), then blocked 
with solution composed of TBS; 0.1% Triton-X100 (only for intracellular antigens); 1% bo-
vine serum albumin (BSA) and 0.2% Teleostean gelatin (Sigma, Germany) (fish gelatin 
buffer, FGB). The same solution was used during the incubations with antibodies. Primary 
antibodies were applied overnight at 4°C. Fluorochrome-conjugated species-specific secon-
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dary antibodies were used for immunodetection. The following antibodies and final dilutions 
were used. Primary antibodies: rabbit anti-GFAP 1:1000 (Dako, Denmark); mouse anti-
ratNestin 1:500 (Pharmingen, Germany); goat anti-Sox2 1:1000 (Santa Cruz, Germany); IgM 
mouse anti-O4 1:100 (Chemicon, USA); rabbit anti-platelet-derived growth factor receptor 
alpha (PDGFRα) 1:100 (Santa Cruz, Heidelberg, Germany); IgM mouse anti-A2B5 1:200 
(Chemicon, UK); mouse anti-Map 2a+2b 1:250 (Sigma, Germany); rabbit anti-doublecortin 
(DCX) 1:500 (NEB, Frankfurt, Germany); mouse anti-2’, 3’-cyclic-nucleotide-3’-
phosphodieesterase (CNPase) 1:200 (Millipore, USA); rabbit anti-NG2 1:200 (Millipore, 
USA); rabbit anti-Galactocerebroside (GalC) 1:200 (Millipore, USA); mouse anti-RIP 1:200 
(Millipore, USA); mouse anti-Myelin Basic Protein (MBP) 1:750 (SMI-94, Sternberger 
Monoclonals Incorporated, U.S.A.). Secondary antibodies: donkey anti-mouse, rabbit conju-
gated with Alexa Fluor 488 (Molecular Probes, Eugene, OR, USA), rhodamine X 1:1000 
(Dianova, Hamburg, Germany) and donkey anti-goat conjugated with Alexa Fluor 568 1:1000 
(Invitrogen, Germany). In cases of detergent-sensitive antigens (i.e. O4, A2B5, GalC and 
NG2), Triton X-100 was omitted from FGB buffer. Nuclear counterstaining was performed 
with 4´, 6´-diamidino-2-phenylindole dihydrochloride hydrate at 0.25 µg/µl (DAPI; Sigma, 
Germany). Specimens were mounted on microscope slides using in Prolong Antifade kit (Mo-
lecular Probes, U.S.A.). Epifluorescence observation and photo-documentation were realized 
using a Leica microscope (Leica Mikroskopie und Systeme GmbH, Germany) equipped with 
a Spot™ digital camera (Diagnostic Instrument Inc, U.S.A.) or an Olympus IX81 inverted 
microscope equipped with Hamamatsu digital camera and Volocity 5.4.1 software (PerkinEl-
mer, Germany).  For each culture condition, 10 randomly selected observation fields, contain-
ing in total 500-1,000 cells, were photographed for cell fate analysis. Expression frequency of 
selected cell type markers was determined for every condition in three independent experi-
ments. 
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Quantitative PCR 
 
RNA extraction from NPCs was performed using RNeasy Mini Kit (Qiagen, Ger-
many) and cDNA was synthetized using Promega reverse transcription Kit (Promega, Ger-
many). Expression analysis was performed by TaqMan gene expression assays kits (Applied 
Biosystems, USA) for the following rat genes: Olig1, Olig2, Id2, NG2, Nestin, PDGFRα, 
CNPase and MBP. Probes and primers were provided by the manufacturer (Applied Biosys-
tems, USA). Rat glyceraldehyde 3-phosphate dehydrogenase was used as a reference gene. 
The following temperature profile was used: activation of polymerase 95°C, 10 min; 40 cy-
cles of denaturing 95°C, 15 s, and annealing/extension 60°C, 60 s. Data was obtained with a 
Rotor-Gene 6000 R Corbett Research (geneXpress, Austria) and analyzed by delta delta Ct 
method [33]. Gene expression under control conditions was used as a calibrator gene.  
 
Statistical Analysis   
 
 Data are presented as means ± SD and statistical analysis was performed using 
PRISM4 (GraphPad, San Diego, CA, USA). P values of < 0,05 were considered to be signifi-
cant acquired by parametric one-way ANOVA-Tukey post hoc. For time course experiments 
two-way ANOVA-Bonferroni post hoc was conducted. All experiments were performed at 
least in triplicate in three independent experiments. 
 
 
Results 
 
Here, we used a neurosphere culture model to analyze the effects of a 3 weeks mesen-
chymal stem cell derived conditioned medium (MSC-CM) treatment of NPCs under prolifera-
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tion conditions with the hypothesis that the MSC-CM might prime the NPCs towards an oli-
godendroglial fate. To test whether the NPCs used in the present study are multipotent self-
renewing progenitors, we grew primary and secondary neurospheres under stringent clonal 
condition (one cell per well) and analyzed for neuronal, astroglial and oligodendroglial differ-
entiation potential of the cells (see supplementary material). Even though the majority of neu-
rosphere derived cells expressed the oligodendroglial progenitor marker O4, as demonstrated 
directly after seeding of the cells, approximately half of the population was positive for the 
neural stem cell markers Sox2 and Nestin. Moreover, the neurosphere derived cells generated 
primary and secondary spheres under clonal conditions and differentiated into DCX express-
ing neurons, GFAP positive astrocytes and MBP positive oligodendrocytes. Cell identity was 
analyzed directly after the 3 weeks stimulation by profiling the cell type specific marker ex-
pression. Cell intrinsic differentiation fate was analyzed after a one week period of growth 
factor withdrawal, and cell lineage restriction was tested by exposing the primed cells to se-
rum, an astroglia inducing activity. Finally, we determined the expression of Olig2 and Id2 
glial fate determinants on proliferating NPCs directly after the three weeks of pre-treatment 
(Fig. 1).   
 
MSC-CM promotes adhesion of proliferating NPCs without interfering with cell prolifera-
tion  
 
In order to study the effects of soluble factors derived from MSCs on proliferating 
NPCs, adult rat neurosphere derived single cells suspensions were treated with increasing 
concentrations of MSC-CM under proliferation conditions, i.e. in the presence of EGF and 
FGF-2 for 7, 14 or 21 days. Importantly, the basic composition of the control medium and 
MSC-CM were identical. One additional control condition was used for some experiments to 
exclude the possibility that the MSC-CM derived effects might be due to the fact that MSCs 
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might have consumed EGF and FGF resulting in conditioned media without growth factors. 
Therefore, NPCs were incubated also with MSC-CM replenished with EGF and FGF-2.  
 
While proliferating NPCs readily re-grew neurospheres in control proliferation me-
dium (Fig. 2A, E, I), sphere formation was reduced in 50% MSC-CM, in 100% MSC-CM and 
in MSC-CM + GF. Instead, cells attached to the plastic surface and formed cellular processes 
(Fig. 2B-D, F-H, J-L). The growth characteristics of the cultures were investigated by Trypan 
blue exclusion cell counting, MTS assay and by determining the number of neurospheres and 
the mean neurosphere diameter. Regardless of the treatment, NPC cultures expanded along 
the three weeks of observation with comparable kinetics by generating similar cell numbers 
(Fig. 2M, N) and by forming similar neurosphere numbers (Fig. 2O) with neurospheres of 
comparable mean diameter (Fig. 2P). The mean diameter of untreated control neurospheres 
was slightly, but not significantly, less compared to the MSC-CM conditions. Moreover, there 
were no differences in the morphology and growth characteristics of cells treated with either 
100% MSC-CM or MSC-CM + GF. Taken together, this indicates that MSC-CM had no ob-
vious influence on the growth kinetics of NPCs. 
 
MSC-CM pre-treatment primes NPCs towards oligodendroglial differentiation under pro-
liferation conditions 
 
The striking effects of MSC-CM on the adherence of NPCs lead us to investigate the 
expression of progenitor markers in the cultures. Therefore, NPCs were cultured in EGF and 
FGF-2 for up to three weeks under control or MSC-CM conditions. Cells were then dissoci-
ated and seeded overnight under serum-free conditions to allow them to attach and fixed and 
stained for stem / progenitor markers. In consistence with our previous report [34], a subpopu-
lation of NPCs in the cultures expressed the neural stem cell marker Nestin (between 10 to 
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15% Fig. 3A, B). The majority of the NPCs expressed the oligodendrocyte progenitor marker 
O4 (appr. 90% Fig. 3I, J) as well as the glial progenitor markers A2B5 (appr. 50% Fig. 3C, 
D), PDFGRα (appr. 35% Fig. 3E, F) and NG2 (appr. 30% Fig. 3G, H). The MSC-CM treat-
ment did not affect the relative proportion of cells expressing one of these stem / progenitor 
markers (Fig. 3B, D, F, H, J). However, the number of RIP-positive oligodendrocytes was 
significantly increased after MSC-CM pre-treatment in a dose-dependant manner from ap-
proximately 0% in the control to 30% in 50% MSC-CM and to 40% in 100% MSC-CM (Fig. 
3K, L). In general, fewer cells were positive for CNPase (appr. 0% in control, 2% after MSC-
CM treatment; Fig. 3M, N), GalC (appr. 2% in control, 10% after MSC-CM treatment; Fig. 
3O, P) or MBP (appr. 0% in control, 10% after MSC-CM treatment; Fig. 3Q, R). Finally, 
there were no GFAP-positive cells (Fig. 3S, T) and only very few cells that expressed the neu-
ronal precursor marker doublecortin (DCX) in control conditions (Fig. 3U, V). The MSC-CM 
treatment did not affect the percentage of the DCX-positive cells (Fig. 3V) and the slight in-
crease of GFAP-positive cells after MSC-CM treatment (Fig. 3T) was not significant. Also 
importantly, there was no difference in marker expression profile in cultures treated with 
100% MSC-CM or MSC-CM + GF (Fig. 3L, N, P, R, T). Most of the NPCs expressed the 
stem / progenitor markers Nestin, A2B5, PDGFRα, NG2 and O4 indicating that the vast ma-
jority of cells in the cultures had indeed an immature character.  
 
Next, quantitative RT-PCR was performed to determine the expression levels of neural 
stem cell and CNS lineage markers and to analyze the effects of the MSC-CM treatment. The 
three weeks MSC-CM treatment significantly enhanced the expression of CNPase- and of 
MBP-mRNA in the NPCs (Fig. 3W). The mRNA expression levels of the progenitor markers 
NG2 and PDGFRα were slightly, but not significantly, reduced, while the expression levels of 
Nestin and the Olig genes were not affected by the MSC-CM treatment (Fig. 3W).  
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These data suggest that MSC-CM primes NPCs under proliferation conditions to dif-
ferentiate into oligodendrocytes. While the presence of MSC-CM induced major changes at 
the mRNA levels, in particular in MBP expression, the cells apparently did not yet express the 
oligodendrocyte phenotype at the protein level, suggesting that the oligodendrocytic pheno-
type at this stage is more advanced on mRNA level than on protein level.  
 
Pre-treatment of NPCs with MSC-CM enhances growth factor withdrawal induced oli-
godendroglial differentiation  
 
We recently noticed that adult rat hippocampus and SVZ derived neurospheres, al-
though being tripotent, differentiate predominantly into oligodendrocytes after growth factor 
withdrawal (GFW) in serum free conditions [34].To determine whether this default differen-
tiation pathway is affected by MSC-CM, NPCs were pre-treated with control proliferation 
medium or MSC-CM for three weeks, dissociated and seeded, and incubated for 7 days in 
serum free conditions in the absence of FGF-2 and EGF. As expected, one week after GFW, 
control-treated NPCs, while still expressing O4 (Fig. 4A, B), differentiated primarily into ma-
ture oligodendrocytes expressing RIP and CNPase (appr. 30% Fig. 4D, F), GalC (appr. 40% 
Fig. 4H), and MBP (appr. 60% Fig. 4J). Interestingly, although MSC-CM treatment did not 
affect the proportion of O4-expressing oligodendrocyte progenitor cells (Fig. 4A, B), it in-
creased the percentage of RIP-, CNPase-, GalC- and MBP-expressing oligodendrocytes after 
GFW (Fig. 4D, F, H, J). We did not observe any MSC-CM effect on the percentage of cells 
that express the astrocyte marker GFAP (Fig. 4K, L). Finally, there were few cells that ex-
pressed the neuronal progenitor markers DCX (less than 4% Fig. 4M, N) and MAP2ab (less 
than 3% Fig. 4O, P) in response to GFW. MSC-CM pre-treatment did not affect the percent-
age of DCX- and MAP2ab-expressing neurons generated after GFW (Fig. 4N, P). Moreover, 
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regardless of the pre-treatment of proliferating NPCs, less than 10% of the cells express neu-
ral stem / progenitor markers (data not shown), indicating that in the absence of growth fac-
tors NPCs are induced to differentiate. Again, in some of the experiments, the MSC-CM was 
replenished with EGF and FGF-2 to exclude the possibility that MSCs might have consumed 
these growth factors and thereby induced the pro-oligodendroglial effects.  The results, as 
demonstrated in Fig. 4D, F, H exclude this possibility. Interestingly, while the GFW condition 
demonstrated the increased oligodendroglial potential of the MSC-CM pre-treated NPCs, the 
mRNA levels of the pro-oligodendroglial determinants Olig1 and Olig2 and of the oligoden-
droglial genes CNPase and MBP were not further enhanced (Fig. 4Q). Taken together, this 
suggests that MSC-CM enhances the oligodendrogenic ability of proliferating NPCs resulting 
in an increased level of oligodendroglial differentiation in response to GFW.  
 
MSC-CM primes proliferating NPCs: acceleration of differentiation and reinforcement of 
oligodendroglial commitment  
 
Based on the fact that MSC-CM encourages proliferating NPCs towards oligodendro-
genesis we asked if this effect involves accelerated oligodendrocyte differentiation / matura-
tion and/or enhanced oligodendrocyte lineage restriction. First, to determine whether MSC-
CM modulates the kinetics of oligodendrogenesis in response to GFW, we analyzed the tem-
poral expression pattern of markers that appear sequentially along the oligodendrogenic proc-
ess as well as astrocytic and neuronal markers. GFW, regardless of the pre-treatment, signifi-
cantly increased the percentage of MBP-expressing mature oligodendrocytes with time (Fig. 
5A). Importantly, the MSC-CM pre-treatment triggered a significant increase in the genera-
tion of MBP-expressing oligodendrocytes 3 and 7 days after GFW (Fig. 5A). The expression 
of GalC and of RIP after GFW significantly increased over time under all conditions analyzed 
(Fig. 5B, C). Moreover, the MSC-CM pre-treatment induced a dose-dependant increase in the 
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percentage of GalC- and of RIP positive cells (Fig. 5B, C).  Although the proportion of 
CNPase-expressing cells transiently increased in all conditions after GFW, only MSC-CM 
pre-treated proliferating NPCs persistently produced such cells. This culminated in a signifi-
cantly higher percentage of CNPase-positive oligodendrocytes compared to the other condi-
tions (Fig. 5D). In addition, in spite of the fact that MSC-CM pre-treated proliferating NPCs 
displayed a slightly higher percentage of GFAP-expressing astrocytes compared to untreated 
NPCs, there was an abrupt decrease in GFAP expression after GFW independently of the pre-
treatment (Fig. 5E). Finally, although minor changes in the percentage of DCX-expressing 
neurons were observed along time after GFW, MSC-CM pre-treatment had no significant 
effect on the generation of DCX-positive cells (Fig. 5F). Together, these findings indicate that 
MSC-CM pre-treatment of proliferating NPCs induces a faster and a more efficient differen-
tiation into oligodendrocytes without affecting the generation of astrocytes and neurons.  
 
Second, we analyzed the possibility that MSC-CM pre-treatment on proliferating 
NPCs might enhance oligodendrocyte lineage restriction. In order to test this hypothesis, 
MSC-CM pre-treated and non pre-treated proliferating NPCs were exposed to FBS, as serum 
has been described as a potent astrogenic stimulus on glial progenitors [35]. As expected, a 
one week stimulation with FBS predominantly induced astroglial differentiation in control-
treated NPCs, since approximately 60% of the cells expressed the astrocyte marker GFAP 
(Fig. 6C), while only approximately 3% and 7% of the cells expressed the oligodendrocyte 
markers MBP and CNPase, respectively (Fig. 6A, B). In contrast, and despite the presence of 
an astrogenic milieu, the MSC-CM pre-treatment generated significantly more MBP- as well 
as CNPase-expressing oligodendrocytes (Fig. 6A, B). Moreover, this effect was at the ex-
pense of astrogenesis, since significantly less GFAP-expressing cells could be observed under 
these conditions (Fig. 6C). The MBP- as well as the CNPase-expressing cells in the MSC-CM 
pre-treated group appeared in clusters, suggesting a clonal effect. Finally, almost no DCX-
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expressing cells were found under this astrogenic condition, regardless of the pre-treatment 
(Fig. 6D). In summary, MSC-CM pre-treatment of proliferating NPCs boosts the oligoden-
drocyte lineage commitment and partially counteracts the astrogenic effect of FBS.  
 
MSC-CM increases the Oligs/Id2 ratio in proliferating NPCs during priming  
 
Next, we reasoned that oligodendroglial priming of NPCs by MSC-CM should involve 
altered expression of pro- and anti-oligodendrogenic fate determinants. Here, the relative ex-
pression of Olig2 and Id2 is a key determinant for oligodendrocyte/astrocyte fate decision 
[19] (Fig. 1). Therefore, proliferating NPC were incubated up to 3 weeks under normal prolif-
eration conditions (control), 50% and 100% MSC-CM, the expression level of Olig2 and Id2 
were analyzed by quantitative RT-PCR, and the Olig2/Id2 ratio was determined for the differ-
ent conditions. While the expression levels of Olig2 did not change within the different condi-
tions (Fig. 7A), MSC-CM drastically reduced the expression of Id2 (Fig. 7B). In order to es-
timate the Olig2/Id2 ratio, the expression level of Olig2 was related to Id2 as a calibrator. 
MSC-CM dose-dependently increased the Olig2/Id2 ratio compared to control conditions 
(Fig. 7C) favoring oligodendrocyte fate decision. In conclusion, the increased Olig2/Id2 ratio 
in MSC-CM-treated NPCs might explain the enhanced oligodendrogenic response to GFW 
compared to non-treated NPCs.  
 
Discussion 
 
Cell progenitor priming as well as cell fate and lineage decisions presumably occur 
while progenitors are still proliferating [12,36-38]. For instance, different combinations of 
growth factors such as PDGFα, FGF-2 and Shh can convert embryonic derived proliferating 
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neurospheres into OPCs containing oligospheres [38,39]. Lithium chloride primes proliferat-
ing NPCs and increases the proportion of cells expressing neuronal markers at the expense of 
gliogenesis [37]. Moreover, FGF-2, heparin and laminin set up adult human brain derived 
proliferating NPCs towards a neuronal fate [36]. Here, we have shown that MSCs prime pro-
liferating NPCs, reinforce oligodendroglial cell fate decision and accelerate the differentiation 
towards oligodendrocytes.  
 
 The conditioned medium derived from MSCs did not impinge on cell proliferation and 
neurosphere formation. However, MSC-CM primed progenitors towards oligodendrocytes as 
the number of RIP-positive cells as well as the mRNA expression levels of the oligodendro-
cyte markers CNPase and MBP were significantly enhanced after a 3 week incubation with 
MSC-CM under proliferation conditions. After growth factor withdrawal the MSC-CM in-
duced elevated predisposition towards oligodengroglial differentiation at the mRNA levels 
consolidated into a higher percentage of RIP-, GalC-, CNPase- and MBP-positive mature oli-
godendrocytes. In a number of experiments, we excluded the possibility that the oligodendro-
glial differentiation effect of the MSC-CM might derive from a consumption of EGF or FGF-
2, suggesting that the MSC-CM indeed contains a pro-oligodendroglial activity, whose iden-
tity is still under investigation. Nevertheless, the present data clearly demonstrate that the pro-
oligodendroglial effect of MSC-CM is dose dependent, although, depending on the gene or 
protein marker analyzed, this dose-dependency might vary.  This might be a consequence of 
minor alterations in the quality of the conditioned media resulting from slightly different fea-
tures of the primary MSCs preparations. Nevertheless, in summary, regardless of the prepara-
tion, a pro-oligodendrogenic effect is always present in the MSC-CM. 
 
The MSC-CM derived oligodendrogenic priming effect on proliferating NPCs rein-
forced the lineage-restriction and enables to overcome an astrogenic milieu. A surprising ob-
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servation within the present work is the notion that the majority of progenitors (appr. 60%) 
that were generated under control conditions differentiated into MBP-expressing oligoden-
drocytes in serum-free conditions. This suggests that the progenitors used in the present study 
where already partly committed to an oligodendroglial fate, which confirms our previous 
work [34]. This tendency to generate oligodendrocytes might have been overlooked in many 
previous studies, since most of the differentiation assays are typically performed in serum-
containing, and thus astrocyte-inducing, media [20,29,40].  
 
The temporal expression pattern analysis of cell type specific markers revealed that 
progenitors grown under control proliferation conditions generate a wave of CNPase-
expressing immature oligodendrocytes in response to growth factor withdrawal. After the 
third day of GFW this CNPase population declines, while the numbers of RIP-, GalC- and 
MBP-expressing mature oligodendrocytes increase with time (Fig. 5). In contrast to NPCs 
that were grown under control condition, progenitors pre-treated with MSC-CM persistently 
generated an increasing number of CNPase-positive cells in response to GFW. In addition, the 
MSC-CM pre-treatment elevated the numbers of MBP, GalC and RIP positive cells. The de-
cline in the percentage of CNPase expressing cells with a simultaneous increase in MBP, 
GalC and RIP positive cells in the control condition is somewhat unexpected, since CNPase 
plays a functional role in oligodendrogenesis and its expression is normally maintained even 
in mature oligodendrocytes [41-44]. The reason for the decline in CNPase expression in the 
control condition and 50% MSC-CM treated cells is unclear at present. One attractive hy-
pothesis might be that sustained expression of CNPase might require additional factors pre-
sent in vivo but not in the control conditions. Nevertheless, MSC might express and secrete 
such a sustained pro-oligodendroglial activity, since the MSC-CM clearly sustainably ele-
vated the percentage of CNPase expressing cells.   
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The molecular mechanism of the MSC-CM induced oligodendroglial activity has still 
to be identified, but it seems to target the regulation of Id proteins. The ratio of the amount of 
Olig and Id2 proteins is a key determinant for oligodendrocyte versus astrocyte fate decision 
[19]. In our previous study, we had already demonstrated that MSC-CM induces Olig2 and 
reduces Id2 expression in neural progenitors that underwent serum-induced differentiation 
[20]. Under proliferation conditions and serum-free differentiation conditions, MSC-CM did 
not increase Olig1 and Olig2 expression, but constrained the expression of Id2 and thus raised 
the Olig2/Id2 ratio. As a consequence, Id2 appears to be a key regulator in the process, and a 
more detailed analysis of the molecular regulation of Id2 expression might be of interest.  
 
CNS remyelination is the main endogenous regenerative mechanism that protects from 
demyelination, in particular in the case of MS. Although progenitors are present around MS 
lesions, migration and differentiation / maturation into myelinating cells is impaired [24,25]. 
The lack of myelin-promoting activities might contribute to the MS related remyelination 
impairment. In addition, aging represents a risk factor, since endogenous remyelination is 
drastically affected in aged subjects [26-28]. First, it has been shown that after demyelination 
in old rats remyelination occurs only in a slow and delayed fashion [26]. This age-related im-
pairment in remyelination is due to a deficient progenitor recruitment and differentiation [27]. 
Thus, while remyelination impairment in MS and in particular during aging is partly derived 
from the failure to differentiate into oligodendrocytes, a lack of sufficient oligodendroglial 
commitment in proliferating progenitors might contribute to this deficiency. The fact that 
MSCs not only induce oligodendrocyte differentiation [20] but also prime proliferating NPCs 
towards an oligodendrocyte fate might have in vivo and clinical relevance when aiming to 
develop remyelinating therapies for MS in young as well as in old patients.  
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In conclusion, MSCs exert a potent oligodendrogenic effect on adult proliferating 
NPCs promoting and enhancing cell fate decision, differentiation and maturation. The identi-
fication of the MSC derived oligodendrogenic activity as well as the clarification of the un-
derlying molecular mechanism are crucial for the development of new therapies for the treat-
ment of demyelinating diseases such as MS. Moreover, clinical situations that require remye-
lination of bare axons such as after spinal cord injury might also profit from such a develop-
ment.  
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Figure Legends 
 
FIG. 1. The oligodendrogenic process of neural stem / progenitor cells and the experi-
mental design. A) In the oligodendroglial lineage, undifferentiated neural stem cells (NSCs) 
undergo sequential steps of cell lineage commitment, differentiation, and maturation involv-
ing different cell types and culminating in myelinating oligodendrocytes (OLs). Due to the 
specific marker expression profile each cell type can be identified during this process. Prolif-
erating (circular small arrow) Nestin-expressing NSCs, follow a specification step to give rise 
to glial progenitor cells (GPCs), characterized by the expression of A2B5 epitope, platelet 
derived growth factor receptor-alpha (PDGFRα) and the chondroitin sulfate proteoglycan 
NG2. In turn, proliferating GPCs can give rise to O4-expressing cycling oligodendrocyte pro-
genitor cells (OPCs) that undergo glial fate decision towards astrocytes or OLs. Several glial 
fate determinants regulate this step, in particular the relative expression levels of Oligs and 
Ids play an important role at the glial branch point. A high Oligs / Id2 ratio implies an oli-
godendrocyte fate decision and vice versa. Therefore, cell lineage commitment and restriction 
might occur in proliferating immature stem / progenitor cells. Next OPCs follow a differentia-
tion process towards immature 2',3'-cyclic nucleotide 3' phosphodiesterase- (CNPase) and 
RIP-expressing OLs. Finally, a maturation process takes place and will give rise to myelinat-
ing OLs, characterized by the expression of Galactocerebroside (GalC) and myelin basic pro-
tein (MBP). B) The experimental of the present work uses a three week (3W) treatment of 
proliferating (circular small arrow) NPCs with MSC-CM. During this period, cell morphology 
and proliferation are followed. Proliferating NPCs give rise to neurospheres that are dissoci-
ated for subsequent experiments and analyses. Cell identity is analyzed directly after the three 
week stimulation by profiling cell type specific marker expression; the intrinsic differentiation 
fate of the cells is analyzed after a one week (1W) period of growth factor withdrawal (GFW); 
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the oligodendroglial cell lineage restriction is tested by exposing the primed cells for 1W to 
serum, an astroglia inducing activity; finally, the expression of Olig2 and Id2 is determined in 
proliferating NPCs directly after the 3W of exposure to MSC-CM.  
 
FIG. 2. Morphology and growth curve of proliferating NPCs. Phase contrast images of 
NPCs in normal proliferation medium (control) (A, E, I), treated with 50% MSC-CM (B, F, 
J), 100% MSC-CM (C, G, K) or MSC-CM replenished with growth factors (MSC-CM + GF) 
(D, H, L). Proliferating NPCs were incubated for 7 days (A-D), 14 days (E-H) and 21 days 
(I-L). Note that under control conditions proliferating NPCs grew as floating aggregates, but 
when the cells were treated with MSC-CM some NPCs attached to the surface of the flask and 
grew adherent. Scale bar = 100 µm. The cell number was determined by Trypan blue exclu-
sion after 7, 14 and 21 days. Growth curves for the different conditions were determined (M). 
The metabolic activity of the cells (N) as well as the number of neurospheres (O) and the 
mean neurospheres diameter (P) were analyzed on day 2, 4 and 7 during the second week of 
incubation with the respective media. Note that there is no significant effect of MSC-CM on 
the NPCs proliferation rate. All experiments were performed at least in triplicate in three in-
dependent experiments. Data are shown as mean +/- SD. For statistical analysis two-way 
ANOVA-Bonferroni post-hoc was performed. 
 
FIG. 3. Cell identity: marker expression profile of pre-treated proliferating NPCs. NPCs 
were dissociated after the 3W exposure to MSC-CM or control conditions, and cells were 
seeded overnight under serum-free conditions. The marker expression profile was analyzed by 
immunocytochemistry and quantitative RT-PCR. Illustrative fluorescence images of the im-
munostainings are shown for: Nestin (red) and DAPI (blue) (A); A2B5 (red) and DAPI (blue) 
(C); PDGFRα (green) and DAPI (blue) (E); NG2 (green) and DAPI (G); and O4 (red) and 
DAPI (blue) (I); RIP (red) and DAPI (blue) (K); CNPase (red) and DAPI (blue) (M); GalC 
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(green) and DAPI (blue) (O); MBP (red) and DAPI (blue) (Q); GFAP (green) and DAPI 
(blue) (S); DCX (green) and DAPI (blue) (K). Scale bar = 10µm. Quantitative analysis show 
the percentage of positive cells for each marker (B, D, F, H, J, L, N, P, R, T and V). Note 
that the number of RIP-positive cells was significantly increased after MSC-CM treatments 
compared to control condition, while there was no significant change for the other tested 
markers after MSC-CM stimulation. (W) Quantitative RT-PCR for glial fate determinants and 
stem / progenitor cell markers. Delta delta Ct method was used for analysis considering 
glyceraldehyde 3-phosphate dehydrogenase as normaliser gene and control condition as cali-
brator. Relative expression levels of Nestin, NG2, PDGFRα, Olig1, Olig2, CNPase and MBP 
after treatment with 100% MSC-CM compared to control condition (dashed line) are shown. 
After 3 weeks of pre-treatment with MSC-CM there was a significant increase in the expres-
sion of CNPase and MBP, while there was a slight decrease in the expression levels of NG2 
and PDGFRα. All experiments were performed at least in triplicate in three independent ex-
periments. Data are shown as mean +/- SD. For statistical analysis one-way ANOVA-tukey 
post-hoc was performed. Asterisks above individual columns indicate significant difference 
compared with control. Asterisks above a line spanning two columns indicate significant dif-
ference between MSC-CM treatments. * = p<0.05; *** = p<0.001. 
 
FIG. 4. Cell intrinsic differentiation fate: GFW response of pre-treated proliferating 
NPCs. NPCs that were exposed under proliferation conditions to MSC-CM or control condi-
tions were dissociated, seeded and incubated for one week under serum-free conditions in the 
absence of growth factors. Cells were fixed and the expression of cell-specific-lineage mark-
ers and fate determinants was analyzed by immunofluorescence and quantitative RT-PCR.  
Illustrative fluorescence images are shown for: O4 (red) and DAPI (blue) (A); RIP (red) and 
DAPI (blue) (C); CNPase (red) and DAPI (blue) (E); GalC (green) and DAPI (blue) (G); 
MBP (red) and DAPI (blue) (I); GFAP (green) and DAPI (K); DCX (green) and DAPI (blue) 
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(M); and MAP2ab (red) and DAPI (blue) (O). Scale bar = 10µm. Quantitative analysis show 
the percentage of positive cells for each marker (B, D, F, H, J, L, N and P). Note the signifi-
cant increase in the percentage of cells that express the oligodendroglial markers RIP, 
CNPase, GalC and MBP when proliferating NPCs were pre-treated with MSC-CM. (Q) 
Quantitative RT-PCR for glial fate determinants and oligodendrocyte markers. Delta delta Ct 
method was used for analysis considering glyceraldehyde 3-phosphate dehydrogenase as 
normaliser gene and control condition as calibrator. Relative expression levels Olig1, Olig2, 
Id2, CNPase and MBP after treatment with 100% MSC-CM compared to control condition 
(dashed line) are shown. All experiments were performed at least in triplicate in three inde-
pendent experiments. Data are shown as mean +/- SD. For statistical analysis one-way 
ANOVA-tukey post-hoc was performed. Asterisks above individual columns indicate signifi-
cant difference compared with control. Asterisks above a line spanning two columns indicate 
significant difference between MSC-CM treatments. * = p<0.05; ** = p<0.01; *** = p<0.001. 
 
FIG. 5. Cell intrinsic differentiation fate: temporal expression of neural markers of pre-
treated proliferating NPCs in response to GFW. NPCs were grown for three weeks in the 
presence of MSC-CM, dissociated and seeded overnight under serum-free conditions. Then, 
the cells were either fixed to analyze the marker expression profile at day 0 or the cells were 
incubated in the absence of growth factors for 3 and 7 days and fixed to analyze temporal 
changes in the marker expression profile. Immunofluorescence was performed for the pres-
ence of differentiating and mature oligodendrocyte-, as well as for astrocyte- and neuron- spe-
cific markers. Quantitative analysis show over-time the percentage of cells that express: MBP 
(A), GalC (B), RIP (C), CNPase (D), GFAP (E) and DCX (F). NPCs pre-treated with MSC-
CM display more MBP-, GalC-, RIP- and CNPase-expressing cells along time than untreated 
NPCs after growth factor withdrawal. All experiments were performed at least in triplicate in 
three independent experiments. Data are shown as mean +/- SD. For statistical analysis two-
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way ANOVA-Bonferroni post-hoc was performed. Asterisks indicate significant difference 
compared with control. ** = p<0.01; *** = p<0.001.  
 
FIG. 6. Cell fate restriction: neural differentiation of pre-treated proliferating NPCs in 
response to astrogenic conditions. NPCs treated for 3W under proliferation conditions with 
or without MSC-CM were dissociated, seeded and incubated for one week in the presence of 
FBS as an astrogenic stimulus. Cells were fixed and cell-specific-lineage marker expression 
was analyzed by immunofluorescence. Quantitative analysis show the percentage of cells that 
express: MBP (A), CNPase (B), GFAP (C) and DCX (D). Note that in despite of astrogenic 
conditions, NPCs pre-treated with MSC-CM display less GFAP-expressing astrocytes and 
more MBP- as well as CNPase- expressing oligodendrocytes than non pre-treated NPCs. All 
experiments were performed at least in triplicate in three independent experiments. Data are 
shown as mean +/- SD. For statistical analysis one-way ANOVA-tukey post-hoc was per-
formed. Asterisks above individual columns indicate significant difference compared with 
control. Asterisks above a line spanning two columns indicate significant difference between 
MSC-CM treatments. * = p<0.05; *** = p<0.001. 
 
FIG. 7. Glial fate determinants expression of pre-treated proliferating NPCs. Proliferat-
ing NPCs were grown for 3 weeks under normal conditions (control), 50% or 100% MSC-
CM. Quantitative RT-PCR was performed to analyze the expression of the pro-
oligodendrogenic transcription factor Olig2 and the anti-oligodendrogenic determinant, Id2. 
Delta delta Ct method was used considering glyceraldehyde 3-phosphate dehydrogenase as 
normaliser gene and control conditions as a calibrator. Expression levels of Olig2 (A) and Id2 
(B) under the different conditions are shown. To determine Olig2/Id2 ratio, Olig2 expression 
levels were quantified using Id2 as a calibrator gene in the respective condition (C). Note that 
while MSC-CM does not affect Olig2 expression it strongly decreases Id2 levels. MSC-CM-
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treated proliferating NPCs displays 6 to 7 fold increase on the Olig2/Id2 ratio compared to 
control conditions. All experiments were performed at least in triplicate in three independent 
experiments. Data are shown as mean +/- SD. For statistical analysis one-way ANOVA-tukey 
post-hoc was performed. Asterisks above individual columns indicate significant difference 
compared with control. Asterisks above a line spanning two columns indicate significant dif-
ference between MSC-CM treatments. ** = p<0.01; *** = p<0.001.  
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